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Abstract 
 Runt related transcription factors (Runx) play an important role in mammalian 
development by regulating the expression of key genes involved in cell proliferation, 
differentiation and growth. The work described in this thesis details the mechanisms by 
which the activity of two members of this family are regulated in human cells. Chapter 
One provides a brief introduction of Runx transcription factors. 
Chapter Two describes the regulation of Runx2 protein by the PI3 kinase/Akt 
pathway in human breast cancer cells. The PI3 kinase/Akt pathway is one of the major 
signal transduction pathways through which growth factors influence cell proliferation 
and survival. It is also one of the most frequently dysregulated pathways in human 
cancers. We identify Runx2 protein, a key regulator of breast cancer invasion as a novel 
substrate of Akt kinase and map residues of Runx2 that are phosphorylated by Akt in 
breast cancer cells. Our results show that phosphorylation by Akt increases the binding 
of Runx2 protein to its target gene promoters and we identify the phosphorylation 
events that enhance DNA binding of Runx2. Our work establishes Runx2 protein as a 
critical effecter downstream of Akt that regulates breast cancer invasion. 
In Chapter Three we describe the subnuclear localization of the tumor 
suppressor protein Runx3 during interphase and mitosis. We find that similar to other 
Runx family members, Runx3 protein resides in nuclear matrix associated foci during 
interphase. We delineate a subnuclear targeting signal that directs Runx3 to these 
nuclear matrix associated foci. Our work establishes that this association of Runx3 
protein with the nuclear matrix plays a vital role in regulating its transcriptional activity. 
xiii 
 
Chromatin immunoprecipitation results show that Runx3 occupies rRNA promoters 
during interphase. We also find that Runx3 remains associated with chromosomes 
during mitosis and localizes with nucleolar organizing regions (NORs), reflecting an 
interaction with epigenetic potential.   
This thesis provides novel insights into various mechanisms by which cells 
regulate the activity of Runx proteins. 
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Chapter 1 
General Introduction 
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General Introduction 
Runt related (Runx) proteins are lineage defining transcription factors that 
regulate cell proliferation and growth [1]. These transcription factors are highly 
conserved throughout evolution and are present from sponges to mammals [2, 3].   Both 
human and mouse genomes contain three Runx genes (Runx1, Runx2 and Runx3) that 
each encode α-subunit [polyomavirus enhancer-binding protein 2 (PEBP2α) /core-
binding factor alpha (CBFα)] that forms a heterodimeric complex with the non-DNA 
binding partner CBFβ. The β subunit enhances the binding of α subunit to DNA by 
conformational changes that unmask its DNA interaction surface [4]. The expression of 
Runx proteins is very tightly regulated both spatially and temporally throughout 
development and adulthood and they control many diverse biological processes. Runx1 
is required for definitive hematopoiesis [5, 6], Runx2 is essential for osteogenesis [7-9] 
and Runx3 regulates neurogenesis [10, 11], T cell development [12] and gastric 
epithelial growth [13].  
 The characteristic feature of Runx transcription factors is a highly 
conserved amino acid motif near the N-terminus of the protein designated as the runt 
domain [14]. This domain is remarkably well conserved amongst all Runx proteins. The 
runt domain binds to runx binding element TGt/cGGT present on the promoters of target 
genes and is also involved in protein–protein interactions and nuclear localization of the 
protein [15, 16].  A second conserved characteristic shared among Runx proteins is a 
VWRPY motif at the C-terminus that mediates interactions with the TLE family of 
corepressor proteins [17]. Other C-terminal domains of Runx proteins activate 
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transcription by recruiting histone acetyl-transferases such as MOZ and MORF [18, 19]. 
Runx2 protein has a polyglutamine- polyalanine motif (Q/A) at the N terminus not 
present in other Runx family members (Figure 1). The function of this motif is currently 
not known. The C-terminus of Runx proteins also contains a 30-40 amino acid 
sequence designated as the nuclear matrix targeting signal (NMTS) [20]. The NMTS is 
highly conserved amongst all Runx proteins. It directs the Runx proteins to distinct 
nuclear matrix associated sites within the nucleus [21]. Runx proteins act as a scaffold 
that facilitates the assembly of regulatory complexes at specific intranuclear sites to 
mediate activation or repression of target genes. Proper subnuclear targeting has been 
shown to be imperative for the biological activity of all Runx proteins [6, 20, 22-24].  
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Figure 1: Structure of Runx proteins. Domains definition by mouse Type I isoform 
residues  
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In mammals all three Runx genes are transcribed from two alternate promoters 
generating two major isoforms. Transcription from the distal P1 promoter gives rise to 
the Type II isoform whereas the proximal P2 promoter generates the Type I isoform 
[14]. Both P1 and P2 promoters contain several Runx binding sites raising the possibility 
of auto and cross regulation amongst Runx family members.  Several in vitro studies 
have attributed either negative or positive regulatory role to these sites through binding 
of Runx proteins [25, 26]. However the in vivo significance of these sites remains to be 
elucidated. 
 Type I and Type II isoforms have distinct 5' untranslated regions (5' UTRs) and 
slightly different N-termini. These different N-termini presumably may interact with 
different cofactors thus having different functions. However to date no isoform specific 
function has been clearly defined for any of the Runx proteins. The two 5' UTRs play an 
important role in translation regulation of Runx proteins. For example in Runx1 the UTR 
arising from the distal P1 promoter is short, has a canonical Kozak sequence and is 
efficiently translated in vitro. The 5' UTR from the proximal promoter is very long and 
contains many ATGs that do not support efficient translation. The translation of Runx1 
Type I isoforms occurs from an internal ribosome entry site (IRES) [27, 28]. In contrast, 
in Runx2 both P1 and P2 5' UTRs are able to mediate IRES dependent translation in 
vitro [28]. It is currently not known whether Runx3 5' UTRs also contain IRES motifs and 
functions. It is hypothesized that IRES mediated translation supports synthesis of Runx 
proteins in conditions when cap-dependent translation is impaired: during mitosis, 
differentiation or stress conditions [28]. Runx mRNAs also undergo alternative splicing 
events producing additional protein isoforms [14]. 
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The activity of Runx proteins has been shown to be both stimulatory when 
associated with coactivators and repressive at other targets when associated with co-
repressors. This diverse activity is in part regulated by multiplicity of post translational 
modifications mediated through various signal transduction pathways.  Indeed several 
modifications such as phosphorylation, acetylation and ubiquitination are known to be 
important modulators of Runx stability and activity [29]. Runx proteins have multiple 
phosphorylation sites that are targets of several kinases such as PKA, PKC, ERK, and 
MAPK that regulate Runx activity [30]. For example phosphorylation of specific residues 
in the C- terminal region of Runx1 by ERK has been shown to increase transactivation 
of Runx1 by specifically disrupting its interaction with the corepressor mSin3A [31]. In 
addition to phosphorylation, Runx proteins are also subject to ubiquitination. In the case 
of Runx1, ERK phosphorylation in addition to increasing transactivation also 
destabilizes the protein by targeting it for ubiquitination and subsequent degradation 
[31]. Runx proteins are also subject to acetylation and deacetylation at lysine residues. 
Acetylation can uncover interaction domains resulting in interaction with new proteins, 
increase protein stability and alter function. Runx3 and Runx1 have been shown to be 
acetylated by p300, which in turn also stimulates transcription [32, 33]. Runx2 and 
Runx3 are also targets of Smurfs that ubiquinate and target these proteins for 
proteosome mediated degradation. Interestingly acetylation of specific lysine residues of 
Runx proteins may increase protein stability by interfering with ubiquination of the same 
lysine residues [29]. Thus a complicated network of regulatory modifications is 
employed upon these proteins for tight functional control. Defining the precise role and 
interplay of these modifications in the regulation of Runx function is essential to 
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understanding how cells modulate the activity of Runx proteins in response to different 
signaling inputs. 
Mutations and aberrant expression of Runx proteins are widely associated with 
various cancers where they can act as both tumor suppressors and oncogenes in a 
context dependent manner.  All three Runx genes have been identified as targets for 
retroviral activation that causes lymphomas in CD2-MYC mice. Runx2 cooperates with 
c-myc to induce T- cell lymphoma in c-myc expressing transgenic mice [34, 35].  Runx2 
is aberrantly expressed in breast and prostate cancer cells and is shown to increase 
their metastatic potential [36]. These studies indicate that Runx transcription factors act 
as oncogenes.  Runx1 protein is also shown to act as a dominant oncogene in myeloid 
leukemias through the formation of fusion proteins such as Runx-ETO or TEL-Runx1 as 
a result of chromosomal translocations [37]. On the other hand haploinsufficiency of 
Runx1 leads to familial platelet disorder, a syndrome that causes predisposition to 
myeloid leukemia [38]. Loss of function mutations of Runx1 are also frequently seen in 
acute myeloid leukemias [39].  These observations hint at a possible tumor suppressor 
function of Runx1. Runx3 is a tumor suppressor of gastric epithelium and is frequently 
silenced in human gastric cancer cells due to hemizygous deletion and 
hypermethylation of the Runx3 promoter region [40-44]. 
The factors that influence the behavior of Runx proteins in a particular context 
are beginning to be understood. For example over expression of Runx1 in primary 
murine fibroblasts induces senescence, but cells lacking p19Arf or p53 function acquire 
tumorigenic properties upon Runx1 over expression [45]. Similarly ectopic expression of 
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Runx2 in the thymus lowers proliferation rate of T-cells whereas Runx2 expression in c-
myc expressing T cells causes T cell lymphoma [46]. The precise downstream targets 
through which Runx proteins exert their oncogenic or tumor suppressive effects are not 
fully known. However multiple genes that regulate cell cycle, cell proliferation, 
differentiation and apoptosis are known to be regulated by  Runx proteins [47]. For 
example, the cell cycle regulator, p21 is a downstream target of both Runx1 and Runx2 
[48-50]. p19ARF is another important target for Runx proteins that regulates cell survival 
(Figure 2) [51, 52]. Gene array analysis in p19ARF null fibroblasts over expressing 
various Runx proteins revealed that these proteins regulate many targets with 
established roles in oncogenesis and development [53]. Because Runx proteins play a 
crucial role in the development and progression of various cancers, it is critical to 
understand the mechanisms that regulate the activity of these transcription factors. 
 
 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
                                                                     
Figure 2: Runx proteins target genes involved in key cellular processes 
 
 
 
Adapted from Blyth et al. Nature Reviews (2005) 5; 376-387 
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Chapter 2 
Regulation of Runx2 activity by the PI3 kinase/Akt pathway 
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Abstract 
Breast cancer is one of the most common cancers; metastasis of the primary 
breast tumor to secondary organs that include the brain, bone and lungs is the leading 
cause of mortality and morbidity among patients. Mechanistically, dysregulation of 
several signaling pathways and ectopic expression of oncogenic transcription factors 
contribute to the development and subsequent metastasis of breast cancer cells.  
PI3Kinase/Akt signaling is one of the most frequently dysregulated pathways in 
breast cancer [54]. Aggressive breast cancers frequently show amplification of Akt 
genes or mutations in other components of the signaling pathway that activate Akt [55, 
56]. It has been shown that the metastatic potential of human breast cancer cells is 
regulated by the PI3kinase/Akt pathway [57]. However, only a handful of downstream 
effectors that regulate aberrant transcriptional programs in response to PI3Kinase/Akt 
signaling have been identified.  
Runx transcription factors (Runx1, Runx2, Runx3) are lineage determining 
transcription factors involved in cell growth, proliferation and differentiation [1]. Runx2 is 
a master regulator of osteoblast differentiation and is essential for bone formation [7]. 
Runx2 is ectopically expressed in breast tumors where it up regulates the transcription 
of several metastasis related genes and contributes to metastasis of breast cancer to 
bone [58, 59]. In osteoblasts Runx2 is known to be a downstream effecter of various 
signaling pathways and several protein kinases have been identified that phosphorylate 
Runx2 and positively or negatively regulate its transcriptional activity [60]. However little 
12 
 
is known about how cancer cells regulate Runx2 activity in response to various 
signaling pathways. 
In this study we show that the PI3Kinase/Akt pathway regulates Runx2 
dependent metastatic potential of breast cancer cells. Using biochemical and cell 
biological approaches we show that Runx2 is a direct substrate of Akt kinase and 
phosphorylation of Runx2 at key residues by Akt enhances its DNA binding. Using 
mutants of Runx2 which are unable to respond to Akt signaling we show that Akt 
regulates Runx2 mediated invasion of breast cancer cells. We propose that Runx2 is an 
important downstream mediator of PI3Kinase/Akt signaling in breast cancer. 
 
 
 
 
 
 
 
 
  
Introduction 
Signal Transduction Pathways 
The most common way by which signal transduction pathways affect cellular function is 
by regulating activity of key transcription factors by post translational modifications 
(PTMs). PTMs are the quickest ways of transducing external signals into the cell. There 
are several known PTM such as amidation, acetylation, sulfation, glycosylation, 
phosphorylation etc (Figure 3).  
Among the known PTMs, phosphorylation is a frequently used modification in 
eukaryotic signaling pathways. Protein phosphorylation is catalyzed by a class of 
enzymes (kinases) that transfer gamma-phosphate from ATP to specific amino acid 
side chains in protein substrate. Some kinases phosphorylate serine and threonine 
amino acids, others act on tyrosine, while some act on all three (dual specificity 
kinases). The reverse hydrolysis of the phosphate moiety from the protein is catalyzed 
by protein phosphatases (Figure 4) [61]. Covalent addition of a phosphate to amino 
acids is rapid, reversible and very low cost to the cell. For example, to synthesize a 100 
amino acid protein, the energy cost for the cell is around 400 high energy phosphates. 
However the same protein can reversibly undergo 400 phosphorylation reactions 
without any loss of activity. The importance of phosphorylation as a PTM is attested by 
the fact that nearly 30% of cellular proteins in eukaryotes are phospho-proteins. 
Addition of a phosphate group to key residues of a protein can induce a conformational 
change in the protein, modify enzyme activity, regulate protein-protein or protein-DNA 
interaction and change the stability of the protein by tagging it for degradation [62]. 
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   Figure 3: Examples of post- translational modifications of proteins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
                                                                              
 
  
 
 
 
15 
 
              
                               
 
 
 
 
 
 
 
                                                  
 
 
 
Figure 4: Protein phosphorylation/ dephosphorylation reaction. 
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Many signal transduction pathways employ a kinase cascade to transduce 
extracellular signals inside the cell.  An external stimulus activates a cell surface 
receptor which has an intrinsic kinase activity which phosphorylates and activates a 
downstream kinase which in turn phosphorylates a second downstream kinase and so 
on (Figure 5). This cascading arrangement of kinases permits signal amplification and 
transmission through the cell to the final intended target. Three kinase signaling 
pathways have taken center stage in cancer research in the recent decade. These 
include the Ras/mitogen-activated protein kinase, the Jak/STAT pathway and the 
PI3Kinase/Akt pathway [63]. 
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Figure 5: Kinase cascade                                           
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 PI3Kinase/Akt pathway 
Many growth factors (insulin like growth factor-1, platelet-derived growth factor, etc.) 
and cytokines (IL2, IL3, etc.) transmit survival signals through the PI3Kinase/Akt 
pathway. PI3Kinases (PI3Ks) are a large kinase family that contains three classes with 
multiple isoforms. Only class IA PI3Ks are described here because this group is clearly 
involved in carcinogenesis. Class 1A PI3Ks consist of a regulatory and catalytic subunit. 
The regulatory subunits of class 1A PI3Ks are encoded by three genes (α, β and ). The 
best characterized amongst them is p85α. It encodes an adapter- like protein with an 
SH2 domain through which it binds to the p110 catalytic subunit [64]. The p110 catalytic 
subunit is also encoded by three genes (α, β, and ) all of which have the same basic 
structure. PI3K activity is very tightly regulated in normal cells. Ligand binding to 
membrane associated receptor tyrosine kinases (RTKs) results in transphosphorylation 
of RTK cytoplasmic tail. The p85 subunit docks to this phosphorylated tail resulting in 
recruitment of PI3K to the plasma membrane. The p110 catalytic subunit now comes in 
close proximity to its lipid substrates in the cell membrane. The RTK–p85 interaction 
also causes a conformational change in the p85-p110 complex that relieves an 
inhibitory effect of p85 on p110 kinase activity [65].  RTKs can also activate PI3K 
indirectly through RAS, which can bind and activate the p110 subunit [65, 66].   
Activated PI3K phosphorylates phosphatidylinositol 4, 5 biphosphate (PIP2) to 
produce phosphatidylinositol 3, 4, 5 triphosphate (PIP3) which serves as a lipid second 
messenger in this signaling pathway.  PIP3 in turn recruits PDK1 (3-phosphoinositide-
dependent protein kinase 1) and Akt (both serine/threonine kinases) to the plasma 
membrane. Phosphorylation of Akt by PDK1 and a second kinase, PDK2 results in full 
19 
 
activation of Akt [67-69]. The major negative regulator of this pathway is PTEN 
phosphatase that converts PIP3 to PIP2 [70] (Figure 6). 
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  Figure 6 : Schematic representation of PI3Kinase/Akt pathway 
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 In mammals three isoforms of Akt have been identified, Akt1/PKB , Akt2/PKBß, 
and Akt3/PKB . These isoforms are products of distinct genes but are highly 
homologous and exhibit >80% protein sequence similarity [71]. All three AKT isoforms 
have three conserved domains, an N-terminal lipid-protein interaction domain termed 
the pleckstrin homology (PH) domain through which Akt interacts with PIP3, a central 
kinase catalytic (CAT) domain and a C-terminal extension (EXT) containing a regulatory 
hydrophobic motif (Figure 7). AKT is activated by phosphorylation of critical residues in 
catalytic (by PDK1) and hydrophobic regulatory domain (by PDK2). Akt in turn 
phosphorylates serine and threonine residues present in arginine rich regions of its 
target substrates [72]. AKT is the primary kinase downstream of PI3Kinase and has a 
number of substrates that contribute to growth, survival and metabolism which when 
dysregulated leads to malignant transformation (Figure 8).  
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Domain definition with AKT1 residue numbers, PH- Pleckstrin Homology Domain, AKT1 
(1-107); Linker region, AKT1 (108-148); CAT – Catalytic Domain, EXT – C-terminal 
Extension, AKT1 (409-480).  
 
Figure 7:  Pairwise % identity in Akt domains 
 
 
 
                                                         Adapted from Kumar et al. Oncogene (2005) 24: 7493-7501 
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Figure 8 : List of well known protein kinase B (PKB)/ Akt substrates 
 
  
                                                                       Adapted from Brazil et al. TIBS (2001) 26: 657-66 
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PI3Kinase/Akt pathway and metastasis 
Mutations that activate the PI3Kinase/Akt pathway are intimately associated with the 
development and progression of several cancers.  Mechanisms for activation of Akt 
include loss of negative regulators of the pathway such as, tumor suppressor PTEN [73, 
74] or conversely amplification or activating mutations of positive regulators such as 
phosphoinositide 3'-kinase, Akt [75-77] or the growth factor receptors themselves. 
Activation of Akt promotes cellular survival as well as resistance to chemotherapy 
and/or radiation therapy [78-80]. Not surprisingly, Akt activation is a poor prognostic 
factor in various cancers.  
 In addition to its role in promoting tumor initiation, Akt also plays a major role in 
cancer metastasis. During metastasis cancer cells detach from surrounding tissue, 
degrade extracellular matrix by producing various matrix mettaloproteinases, enter the 
blood or lymphatic circulation (intravasation), travel to distant organs, exit from 
circulation (extravasation), to form secondary tumors and finally, establish an adequate 
blood supply by forming new blood vessels (angiogenesis) (Figure 9). Normal epithelial 
cells require survival signals from surrounding cells and extracellular matrix and 
undergo a specialized form of cell death termed anoikis when they are detached from 
surrounding tissue. Activated Akt signaling protects metastatic carcinoma cells from 
anoikis by engaging an anti apoptotic pathway [81]. For example, AKT prevents release 
of cytochrome c from mitochondria and phosphorylates and inactivates the pro death 
protease, caspase 9, and the pro-apoptotic factor BAD.  The Akt pathway also regulates 
the production of matrix metalloproteinases [82] and vascular endothelial growth factors 
(VEGF) in a variety of tumor cells [83]. VEGF family of proteins is comprised of crucial 
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angiogenic cytokines involved in the development and survival of tumor vasculature. 
The central role of dysregulated PI3K/Akt signaling in cancer initiation and metastasis 
makes it an attractive drug target for treatment of cancers and several drugs that 
selectively block this pathway have been developed to target cancer cells [84-86]. 
However, further understanding of the complexity of the regulation and downstream 
targets of this pathway is necessary in order to develop focused therapies with least 
toxicity but maximal clinical benefits. 
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Figure 9 : Schematic of steps involved in cancer metastasis 
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Overview of Runx2 protein 
Runx2 protein is essential for mammalian bone development. It is required for both 
intramembranous and endochondral bone development as well as tooth 
morphogenesis. Runx2 knockout in mice causes complete absence of bone formation 
[9]. In humans, haploinsufficiency of Runx2 leads to cleidocranial dysplasia, 
characterized by skeletal and dental abnormalities [87]. Like all Runx family members, 
transcription of Runx2 occurs from two distinct promoters, giving rise to two major 
isoforms that differ in their amino termini. The distal P1 promoter drives expression of 
the type II MASNS isoform, while the proximal P2 promoter drives expression of the 
type I MRIPV isoform. Mature osteoblasts and hypertrophic chondrocytes express the 
type II isoform while type I is found in less-differentiated osteoblast and chondrocyte 
precursor cells [88].  Alternative splicing of Runx2 mRNA results in additional protein 
isoforms. In addition to cap-mediated translation, mRNA of both types I and type II 
isoforms can be translated via internal ribosomal entry sites (IRES) found in the 5′-
untranslated regions  [30].   
 At the molecular level, Runx2 acts as a transcription factor for genes expressed 
in hypertrophic chondrocytes and osteoblasts. Runx2 protein is first detected in 
preosteoblasts, and the expression is up regulated in immature osteoblasts, but down 
regulated in mature osteoblasts. Runx2 directs commitment of multipotent 
mesenchymal cells to osteoblast lineage, blocking their differentiation into 
chondrocytes. Runx2 induces the differentiation of mesenchymal cells into immature 
osteoblasts, directing the formation of immature bone. Runx2 acts as a master regulator 
of bone formation and directly/ indirectly controls the expression of several key genes 
28 
 
required for early osteoblast differentiation (i.e., Collagen 1, oscteocalcin, osteopontin, 
alkaline phosphatase, bone sialo protein etc.) [60]. 
 Apart from its well characterized function in bone development Runx2 is also 
expressed in low amounts in normal breast epithelium where its function remains 
unclear. Otto et al. first documented the expression of the Runx2 gene in mammary 
epithelium of mice in vivo suggesting that Runx2 has a role in the mammary gland 
function [89].  Runx2 was shown to regulate the expression of beta casein and 
osteopontin in mammary epithelial cells [90]. Interestingly, whereas Runx2 levels are 
very low in normal breast epithelial cells, its expression increases dramatically in breast 
cancer cells, with highly metastatic breast cancer cell lines showing highest expression 
of Runx2 protein [91]. Runx2 enhances the metastatic potential of breast cancer cells by 
up regulating the expression of several factors that contribute to facilitating the process 
of metastasis, i.e., VEGF, several matrix metalloproteinases (MMP2, MMP9, MMP13) 
and bone sialoprotein (BSP) [92] (Figure 10). These observations are further 
corroborated by the finding that high level of Runx2 protein is seen in many human 
breast cancer patient samples and its expression positively correlates with metastasis 
and poor clinical outcome of the disease [93]. Several breast cancer cell lines aberrantly 
express genes usually restricted to bone cells, including BSP and osteoclacin (OC). The 
term 'osteomimicry' has been coined to describe this expression of bone-related genes 
in metastatic cancers and these genes are thought to help tumor cells home and grow 
in the bone micro environment. Up regulation of Runx2, the master regulator of bone 
formation in metastatic breast cancer cells contributes to the expression these skeletal 
related genes in breast cancer cells [92, 94]. 
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Figure 10: Runx2 regulates the metastatic potential of breast cancer cells by 
activating the expression of metastasis related target genes in breast cancer 
cells. 
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The activity of Runx2 protein is regulated at multiple levels, including 
transcription, translation, and post-translational modification. Post-translational 
modification, especially phosphorylation, is an important regulatory mechanism of 
Runx2 activity. Runx2 is phosphorylated by several kinases in response to various 
signaling molecules which results in differential effect on Runx2 function. The most well 
studied amongst them is Mitogen-activated protein kinase MAPK/ extracellular signal-
regulated kinase (ERK) pathway. Several studies have shown that the MAP kinase 
pathway  phosphorylates and increases the transcriptional activity of Runx2 [95-97]. 
Fibroblast growth factor 2 (FGF2) treatment of osteoblasts increases Runx2 
phosphorylation and Runx2 dependent osteoclacin gene expression in a MAPK 
dependent manner [98]. In vivo transgenic mice overexpressing constitutively active or 
dominant negative mutants of MEK1 in osteoblasts show stimulation or inhibition of 
Runx2 phosphorylation respectively and Runx2 dependent bone development [82, 99].  
Other kinases such as Protein kinase A are also known to phosphorylate and increase 
the transcriptional potential of Runx2 [100].  
Phosphorylation also negatively regulates Runx2 transcriptional activity [101]. 
Phosphorylation of residues in the C- terminus of Runx2 by GSK3β inhibits Runx2 
transactivation. Mice heterozygous for GSK-3 therefore, have increased bone formation 
[102]. Phosphorylation also regulates Runx2 activity in multiple phases of the cell cycle 
[103]. Cyclin D1/CDK4 phosphorylate Runx2 targeting it for subsequent ubiquitination 
and proteasomal degradation [104, 105]. Cyclin B/CDK1 regulates phosphorylation of 
Runx2 during mitosis [106].   
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Most of these studies describing the regulation of Runx2 by phosphorylations 
have been done in osteoblasts. Very little is known about how kinase signaling 
regulates Runx2 activity in breast cancer cells. This study defines the role of 
PI3Kinase/Akt signaling in regulating the DNA binding activity of Runx2 in breast cancer 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
Materials and Methods 
Cell Culture and treatments 
Metastatic human breast cancer cell line SUM159 (kind gift from Dr A. Mercurio, 
Department of Cancer Biology UMASS Medical School) was cultured in Ham’s F12 
media (Hyclone) supplemented with 5% fetal bovine serum (Atlanta), 10mg/ml insulin, 
2mg/ml hydrocortisone and 20mM L-glutamine. Human prostate cancer cell line (PC3) 
and non metastatic human breast cancer cell line (MCF7) were purchased from 
American Type Culture Collection (ATCC). PC3 cells were cultured in T media (Gibco) 
supplemented with 5% fetal bovine serum and 20mM L-Glutamine. MCF7 cells cultured 
in DMEM media supplemented with 10% fetal bovine serum, 2mM penicillin. 293T cells 
were cultured in DMEM media supplemented with 10% fetal bovine serum and 20mM L-
glutamine. To block PI3Kinase/Akt signaling, cells were treated with 20µM LY294002 
(Cell Signaling) or 20µM triciribine (EMD4Biosciences) for the indicated amount of time 
and harvested for analysis. Cells were transfected with various plasmids using 
lipofectamine 2000 (Invitrogen). 
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Bacterial and Mammalian Expression Plasmids 
GST tagged Runx2 pGEX bacterial expression plasmid was a kind gift from Dr M. 
Montecin (Universidad Andres Bello, Santiago, Chile). GST tagged deletion constructs 
of Runx2 were made by amplification of desired Runx2 fragments with primes flanked 
by 5’ BamH1 (forward) and Xho1 (reverse) restriction sites. The resulting PCR product 
was digested and ligated with pGEX vector (GE Health Care Life Sciences). Mammalian 
FLAG tagged expression vector of Runx2 was made by transferring Runx2 cDNA from 
pGEX vector to pCMV2 vector (Stratagene). All single and multiple point mutation 
constructs of Runx2 were synthesized using Single or Multi Site Directed Mutagenesis 
kit (Stratagene) according to manufacturer’s instructions. Constitutively active and 
dominant negative mammalian expression constructs of Akt were purchased from 
Addgene (Addgene plasmid 9008 and 9030). IRES-GFP cassette was inserted at the 
carboxy terminus of both constructs to monitor transfection efficiency. The construction 
and transduction procedure for adenovirus expressing Runx2 and control are reported 
previously [91]. Wild type and mutant Runx2 lentiviral particles were generated utilizing 
Lentiviral Gateway System (Invitrogen).  Wild type and mutant Runx2 cDNAs were 
cloned into pENTR4-FLAG vector and IRES-GFP cassette was inserted at the carboxy 
terminus of all constructs to monitor transfection efficiency. The resulting entry vectors 
were then recombined with lentiviral destination pLenti-CMV-Blast-DEST vector using 
Gateway LR clonase enzyme mix according to manufacturer specifications (Invitrogen).  
Lentiviral particles were generated in 293T cells (Invitrogen) by transient transfection of 
Runx2 constructs along with packaging plasmids. Infected particles were collected after 
48 hours of transfection and used to infect SUM159 and MCF7 cells in the presence of 
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polybrene.  Runx2 shRNA and control lentivirus used to make stable SUM19 cell line 
are described previously [107]. 
 
Protein purification and in vitro kinase assay 
GST fusion proteins including GST, GST-WT Runx2 (full length), GST-9A Runx2 (full 
length), GST-WT Runx2 (2-107), GST-WT Runx2 (107-240), GST-WT Runx2 (240-528) 
were expressed in BL21 RP codon plus cells (Stratagene) and purified using glutathione 
agarose beads according to manufacturer’s instructions (Amersham Pharmacia). The 
quality of purification was assessed by resolving the proteins on 10% SDS PAGE 
followed by coomassie staining. For in vitro kinase assays purified proteins were 
incubated for 30 minutes with 100ng of purified Akt (upstate) in the presence of [γ-32P] 
ATP in kinase buffer (25mM Tris pH 7.5, 10mM MgCl2 and 5mM βglycerophosphate). 
The samples were resolved on 10% SDS PAGE gel and autoradiographed. 
 
Electrophoretic Mobility Shift Assay 
Nuclear extracts were prepared according to the method of Dignam et al [108]. Runx 
consensus probe was labeled with [γ-32P] ATP for 30 minutes at 37°C with T4 
polynucleotide kinase (New England Biolabs) and purified using G-25 Sephadex column 
(Roche). Runx binding sites were mutated to generate corresponding mutant probe for 
competition assays. DNA-protein binding reactions were carried out by incubating 10 
fmol of radiolabeled probe with nuclear extracts, purified Runx2 or in vitro transcribed 
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and translated (IVTT) Runx2 protein at room temperature for 20 minutes. Protein-DNA 
complexes were resolved on 4% (40:1) nondenaturing polyacrylamide-Tris-borate-
EDTA gel at 200 V for approximately 90 minutes at 4°C. For competition assays 100 
fold excess of wild type or mutant probe was included in the reaction. For supershipshift 
analysis, 2μg of Runx2 M-70 antibody (Santa Cruz) was incubated with nuclear extract 
at room temperature for 30 min prior to the addition of probe. Gels were dried and 
autoradiographed at −70°C. 
 
Western Blot 
Total protein extracts, nuclear extracts, GST fusion proteins or immunoprecipitated 
complexes were diluted in 4X sample loading buffer (250mM Tris pH 6.8, 8%SDS, 
40%glycerol and 100mM DTT), boiled for 5 min and centrifuged at 16,000 × g for 1 min.  
Appropriate amounts were loaded onto 10% SDS-polyacrylamide gels and transferred 
to a polyvinylidene difluoride (PVDF) Immobilon-P membrane (Millipore) for 90 minutes 
at 200mA in a wet transfer apparatus (Biorad). Membrane was incubated with 
appropriate dilution of specific primary antibodies followed by incubation with 
corresponding HRP tagged secondary antibodies. Desired proteins were detected with 
Western Lightning Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences). 
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Chromatin Immunoprecipitation 
SUM159 cells over expressing Runx2 were cross linked in 1X PBS with 1% 
formaldehyde for ~3 min and the reaction was quenched by the addition of glycine at a 
final concentration of 250 mM for 10 min. Cells were washed with PBS and incubated in 
lysis buffer A (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA pH 8, 10% Glycerol 
(Sigma G5 150), 0.5% NP-40 (Igepal CA-630, Sigma), 0.25% Triton X-100, 25μM MG-
132, 1X Complete protease inhibitor (CPI) cocktail (Roche)), to lyse the cells. Cells were 
centrifuged for 10 minutes and the pellet was resuspended in lysis buffer B (10 mM Tris-
HCl pH 8, 200 mM NaCl, 1 mM EDTA pH 8, 1 mM EGTA, MG-132, 1X CPI). for 10 min, 
followed by centrifugation for 5 min at 40C. Pellet was resuspended in lysis buffer C (10 
mM Tris-HCl pH 8, 100 mM NaCl, 1 mM EDTA pH 8, 1 mM EGTA, 0.1% Sodium 
deoxycholate (Sigma), 0.5% N-lauroylsarcosine (Sigma), MG-132, 1X CPI) and 
incubated on ice in order to release the chromatin fraction. Chromatin was fragmented  
with Fisher Scientific Sonic Dismembrator fitted with a 1.6mm tip (Fischer Scientific) at 
power 10%, 7 Pulses (10seconds each) to generate DNA fragments of approximately 1 
Kb.  After sonication cell debris was removed by centrifugation at 14,000g for 5 min. 
One percent of the supernatant was kept as input. Rest of the supernatant containing 
protein-DNA complexes was incubated overnight with 4 μg of  Runx2 rabbit polyclonal 
antibody (M70 antibody, Santa Cruz) and 4μg of normal rabbit IgG (Santa Cruz) 
followed by 3 hr incubation with protein A/G-conjugated agarose beads (Santa Cruz).  
Protein A/G bead complexes were washed with the following buffers: low salt (20mM 
Tris-Cl, pH 8.1, 150mM NaCl, 1% Triton X-100, 2mM EDTA, 1X Complete protease 
inhibitor cocktail), high salt (20mM Tris-Cl, pH 8.1, 500mM NaCl, 1% Triton X-100, 2mM 
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EDTA), LiCl buffer (10mM Tris-Cl, pH 8.1, 250mM LiCl, 1% Sodium deoxycholate, 1% 
Nonidet P-40, 1mM EDTA), and twice in TE (10mM Tris-Cl, pH 8.1, 1mM EDTA) 
protein-DNA complexes were eluted in 1% SDS/100mM NaHCO3 (elution buffer) and 
cross-linking was reversed by incubation at 65oC for overnight in elution buffer and 
300mM sodium acetate (pH 5.2).  Later DNA was purified by phenol-chloroform 
extraction followed by ethanol precipitation and then resuspended in TE for quantitative 
PCR. ChIP enrichment was determined as a quantitative measure reflecting the 
percentage of input. Primers flanking Runx2 binding element in human MMP13 
promoter region where used to assess the Runx2 occupancy. Primers amplifyming 
promter region of MARK3 gene were used as negative control. The following is the 
sequence of primers used for CHIP assay 
MMP13 (F) 5'-GTCGCCACGTAAGCATGTTT-3' 
MMP13 (R) 5'-CATCTTGAATGGTGGTGCCT-3' 
MARK3 (F) 5'-ATCCGGATGGCATTTAGCTG-3' 
MARK3 (R) 5'-AGTCAGGTTCTCGCCAACAA-3' 
 
 
RNA isolation cDNA synthesis and Quantitative Real Time PCR 
RNA was isolated using trizol reagent (Invitrogen). Prior to cDNA synthesis DNA was 
removed from RNA using DNA free RNA kit (Zymo). Superscript III (Invitrogen) was 
used to synthesize cDNA. Relative transcript level of each gene was determined using 
ABI PRISM 700 system (Applied Biosystems) by measuring fluorescence of SYBR 
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Green (BioRad). GAPDH or mCox genes were used as reference. Following primer 
sequences were used: 
MMP2 (F) 5'-TGATGTCCAGCGAGTGGAT-3' 
MMP2 (R) 5'-ACGACGGCATCCAGGTTAT-3' 
MMP9 (F) 5'-CCTGGAGACCTGAGAACCAATC-3' 
MMP9 (R) 5'-CCACCCGAGTGTAACCATAGC-3' 
MMP13 (F) 5'-TCTGAACTGGGTCTTCCAAAA-3' 
MMP13 (R) 5'-GCATCTACTTTATCACCAATTCCT-3' 
VEGF (F) 5'-CCTTGCTGCTCTACCTCCAC-3' 
VEGF (R) 5'-CCATGAACTTCACCACTTCG-3' 
mCox (F) 5'-GGGAATTGCGTAAAGGGATA-3' 
mCox (R) 5'-TGAGGTCCTGCTTTGTCCTT-3' 
GAPDH (F) 5'-TGTGGTCATGAGTCCTTCCA-3' 
GAPDH (R) 5'-ATGTTCGTCATGGGTGTGAA-3' 
 
Invasion Assay 
Cells were analyzed for invasion through Matrigel 24 well plates according to 
manufacturer’s instructions (BD Biosciences). Briefly, cells were suspended in serum 
free media and 50,000 cells were placed on each Matrigel insert. 700ul of NIH3T3 
conditioned media was added to the bottom chambers of the plates. Cells were allowed 
to migrate for indicated times at 37oC. Non invading cells were removed by scrubbing 
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and cells that had invaded through the Matrigel were fixed and stained using HEMA 3 
stain kit (Fisher). Cells were counted manually under a light microscope.  
Immunoprecipitation 
FLAG tagged Runx2 was over expressed in 293 T cells using Lipofectamine 2000 
(Invitrogen). Cell lysates (1mg/ml in lysis buffer: 20 mM HEPES, 10 μM ZnCl2, 1 mM 
MgCl2, 250 mM NaCl, 0.1% Triton X-100, supplemented with  MG132, protease and 
phosphatase inhibitors) were incubated with 50µl of agarose conjugated FLAG-M2 
beads (Sigma) at 4°C for 2 hours for Runx2 precipitation. Beads were washed three 
times in wash buffer (20 mM HEPES, 10 μM ZnCl2, 1 mM MgCl2, 150 mM NaCl, 0.1% 
Triton X-100, 1 mM PMSF, 10 μg/ml aprotinin and leupeptin), followed by SDS-PAGE 
and western blot. Phosphorylation level of Runx2 protein was detected by a general 
phospho serine/threonine antibody (BD). Total Runx2 protein was detected using rabbit 
FLAG antibody (Sigma). Blot was probed with Cbfβ antibody to detect co 
immunoprecipitation of Cbfβ with Runx2. 
 
In Situ Immunofluorescence microscopy 
 Cells were grown on gelatin-coated cover slips and next day cell were processed for in 
situ immunofluorescence. In brief, cells were rinsed twice with ice cold PBS and fixed 
using 3.7% formaldehyde in PBS for 10 min on ice. After washing once with PBS, cells 
were permeabilized in 0.1% Triton X-100 in PBS for 15 to 20 min and washed twice with 
PBSA (0.5% BSA in PBS). Fixed cells were incubated for 1 hr with primary antibody at 
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37oC.  Cells were extensively washed with PBSA and incubated with FITC conjugated 
secondary antibody at 37oC. Nuclear DNA or chromosomes were visualized by DAPI 
(4', 6-diamidino-2-phenylindole) staining.  Images were recorded using an 
Epifluorescence Zeiss Axioplan 2 (Zeiss MicroImaging Inc.) microscope equipped with a 
charged coupled device. Images were captured and analyzed by MetaMorph Imaging 
Software (Molecular Devices). 
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Results  
Runx2 regulates the expression of metastasis related genes and modulates the 
invasive potential of SUM159 breast cancer cells 
For our present study to understand the role of the PI3Kinase/Akt pathway in regulating 
the activity of Runx2 in breast cancer cells, we used SUM159 breast cancer cell line 
which was derived from a primary breast tumor with anaplastic carcinoma. This cell line 
has significant amount of ectopic Runx2 expression and high basal activity of the 
PI3kinase/Akt pathway due to an activating mutation in the kinase domain of the 
PI3KCA gene (H1047L) [109]. We initially examined the effect of modulating Runx2 
activity on metastatic marker gene expression and invasion in SUM159 cells. For this 
purpose we generated a stable SUM159 cell line in which Runx2 protein was depleted 
using short hairpin RNA (shRNA) lentivirus. Western blot analysis of cell lysates shows 
that Runx2 is robustly expressed in SUM159 cells and its protein levels are nearly 
depleted by shRNA. Reduction of Runx2 levels decreases expression of several 
metastasis related genes (MMP2, MMP9, MMP13 and VEGF) (Figure 11). In 
complementary functional studies the effect of Runx2 depletion on the invasive potential 
of SUM159 breast cancer cells was examined in Matrigel transwell assays. Depletion of 
Runx2 significantly diminishes invasion of SUM159 cells (40-50% less invasion) (Figure 
12).  
  We examined the effect of Runx2 over expression on expression levels of 
MMP2, MMP9, MMP13 and VEGF by RT-QPCR using SUM159 cells transduced with 
Runx2 or control GFP adenovirus. Runx2 over expression dramatically increased the 
42 
 
expression of all four genes in SUM159 cells (Figure 13). Taken together these results 
indicate that Runx2 modulates the invasive properties of SUM159 breast cancer cells 
and regulates the expression of metastasis related proteins supporting extracellular 
matrix remodeling or angiogenesis. 
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 Figure 11: Runx2 regulates the expression of metastasis related genes in 
SUM159 breast cancer cells 
Expression levels of metastasis related markers were monitored in SUM159 cells in 
which Runx2 protein was depleted using shRNA lentivirus. Runx2 protein was detected 
by western blotting using whole-cell lysates (left panel). B23 protein served as internal 
loading control. Endogenous mRNA levels of metastasis-related genes were measured 
by RT-QPCR analysis of total cellular RNA in response to modulation of Runx2 levels 
(right panel). Data were normalized to GAPDH mRNA levels. Experiments were 
performed in two independent biological samples each with two technical replicates. 
Error bars represent SD. p values based on one-tailed Student’s t test are indicated. 
 
  
 
 
 
 
 
 
                             NS            Runx2 shRNA 
 
Figure 12 : Runx2 depletion reduces the invasive potential of SUM159 breast 
cancer cells 
The effect of Runx2 on cell invasion was monitored by Matrigel transwell assays using 
SUM159 cells that express non silencing (NS) or Runx2 shRNA. Cells were allowed to 
invade for 10 hours at 37°C towards NIH3T3 conditioned medium. We counted two 
random fields in two wells each for three independent experiments. The data are 
presented as the number of invaded cells per field (p values based on one-tailed 
Student’s t test are indicated). Error bars represent SD. Representative images are 
shown. 
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Figure 13: Runx2 regulates the expression of metastasis related genes in SUM159 
breast cancer cells 
Runx2 protein was over expressed in SUM159 cells using adenovirus. Whole-cell 
lysates were prepared to detect Runx2 protein in GFP and Runx2 over expressing cells 
by western blot (left panel). B23 protein was used as internal loading control. Total RNA 
was utilized to examine endogenous levels of metastasis related genes by RT-QPCR 
analysis in response to modulation of Runx2 levels (right panel). Data were normalized 
to the GAPDH signal.  
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PI3Kinase/Akt pathway controls the levels of Runx2 responsive genes and 
invasive properties of breast cancer cells 
We next evaluated whether PI3Kinase/Akt signaling controls Runx2 dependent gene 
expression in SUM159 breast cancer cells. We applied either LY294002, a reversible 
inhibitor of phosphoinositide 3-kinase, or Triciribine, a cell-permeable tricyclic 
nucleoside that inhibits Akt phosphorylation.  Phospho-Akt (p-Akt) and total Akt levels 
were detected by western blot to confirm that the inhibitors were indeed blocking Akt 
activation (Figure 14). Blocking the PI3Kinase/Akt pathway reduces the expression of 
metastasis related Runx2 responsive genes (MMP2, MMP9, MMP13 and VEGF) in 
SUM159 cells (Figure 14). In complementary functional studies, inhibition of 
PI3Kinase/Akt signaling with either LY294002 or Triciribine substantially reduces the 
invasive potential of SUM159 cells (Figure 15). Taken together our results suggest that 
both PI3Kinase and Runx2 are important mediators of breast cancer cell invasion. 
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Figure 14: PI3Kinase/Akt pathway controls the levels of Runx2 target genes in SUM159 
breast cancer cells 
Endogenous PI3Kinase/Akt activity was blocked by treating SUM159 cells with either 
20µM of LY294002 (LY) (A) or Triciribine (Tri) (B). Total cellular protein and RNA 
samples were collected at indicated time points. Phosphorylated and total Akt were 
detected by western blot analysis (lower panels). The mRNA levels of Runx2 target 
genes were measured by RT-QPCR analysis, and data were normalized to GAPDH 
mRNA levels (upper panels). Experiments were performed in two independent 
biological samples each with two technical replicates. Error bars represent SD. p values 
based on one-tailed Student’s t test are indicated. 
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 Figure 15: PI3Kinase/Akt pathway is required for invasion of breast cancer cells 
Untreated SUM159 breast cancer cells (control) or cells treated with either LY294002 
(LY) or triciribine (Tri) were plated on Matrigel inserts for invasion assay. Cells were 
allowed to invade for 10 hours at 37°C towards NIH3T3 conditioned medium. We 
counted two random fields in two wells each for three independent experiments. The 
data are presented as the number of invaded cells per field (p values based on one-
tailed Student’s t test are indicated). Error bars represent SD. Representative images 
are shown. 
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PI3Kinase/Akt signaling regulates DNA binding of Runx2 in breast and prostate 
cancer cells  
To address the mechanism by which the PI3Kinase/Akt pathway regulates biological 
activity of Runx2, we examined how protein levels and DNA binding activity respond to 
modulation of PI3Kinase/Akt signaling in breast cancer cells. We treated SUM159 cells 
with LY294002 and prepared whole cell and nuclear extracts. p-Akt and total Akt levels 
were detected in cell extracts by western blotting to confirm that LY294002 was indeed 
blocking the PI3kinase/Akt pathway. We did not observe any changes in the protein 
levels of Runx2 in nuclear extracts of cells treated with LY294002 (Figure 16A). To test 
if the PI3Kinase/Akt pathway affects the DNA binding potential of Runx2 we subjected 
nuclear extracts of control and LY294002 treated SUM159 cells to Electrophorectic 
Mobility Shift Assay (EMSA). On EMSA, using Runx consensus oligonucleotide probe, 
nuclear extracts from SUM159 control cells formed specific Runx2-DNA complex. 
Blocking PI3kinase/Akt signaling drastically reduces the formation of the Runx2-DNA 
complex indicating that the PI3Kinase/Akt pathway enhances the DNA binding of Runx2 
in breast cancer cells (Figure 16A). This effect of was not restricted to breast cancer 
cells as PC3 prostate cancer cells treated with LY294002 also show similar reduction in 
the DNA binding activity of Runx2 (Fig.16 B). 
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Figure 16A: PI3Kinase/Akt pathway regulates DNA binding of Runx2 in breast 
cancer cells 
Endogenous PI3Kinase/Akt activity was blocked in SUM159 breast cancer cells by 
treatment with 20µM LY294002 for four hours. Whole cell (WCE) and nuclear extracts 
(NE) were resolved by 10% SDS PAGE and probed with antibodies that detect phospho 
Akt or total Akt (WCE) or Runx2 (NE) (left panels). Runx2 DNA binding activity was 
measured by Electrophoretic Mobility Shift Assays (EMSA) using nuclear extracts and a 
Runx consensus oligonucleotide. Specificity of the Runx2 complex was established 
using binding assays with unlabeled WT or mutant (MT) competitor oligonucleotides as 
well as an antibody (M70; Santa Cruz) that generates a Runx2 supershift (Rx2+ Ab). 
The asterisk (*) indicates a non specific (NS) band (right panel). 
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Figure 16B: PI3Kinase/Akt pathway regulates DNA binding of Runx2 in prostate 
cancer cells  
Endogenous PI3Kinase/Akt activity was blocked in PC3 prostate cancer cells by 
treatment with 20µM LY294002 for four hours. Whole cell (WCE) and nuclear extracts 
(NE) were resolved by 10% SDS PAGE and probed with antibodies that detect phospho 
Akt or total Akt (WCE) or Runx2 (NE) (right panels). Runx2 DNA binding activity was 
measured by Electrophoretic Mobility Shift Assays (EMSA) using nuclear extracts and a 
Runx consensus oligonucleotide. Specificity of the Runx2 complex was established 
using binding assays with unlabeled WT or mutant (MT) competitor oligonucleotides as 
well as an antibody (M70; Santa Cruz) that generates a Runx2 supershift (Rx2+ Ab). 
The asterisk (*) indicates a non specific (NS) band (left panel). 
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We further validated our EMSA data by chromatin immunoprecipitation (ChIP).  We 
blocked PI3Kinase/Akt signaling in SUM159 cells over expressing Runx2 protein and 
processed the cells for ChIP analysis using Runx2 antibody. We analyzed binding of 
Runx2 on MMP13 promoter which has well characterized Runx2 binding elements 
[110]. Inhibition of the PI3Kinase/Akt pathway reduces genomic interactions of Runx2 
with the MMP13 promoter (Figure 17). These results indicate that PI3Kinase/Akt 
signaling enhances the DNA binding potential of Runx2. 
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Figure 17:  PI3Kinase/Akt pathway regulates DNA binding of Runx2 in breast 
cancer cells (ChIP assay) 
SUM159 cells over expressing WT Runx2 were treated with PI3Kinase/Akt inhibitors, 
LY294002; LY or Triciribine; Tri for four hours and subjected to Chromatin 
Immunoprecipitation assay (ChIP) using Runx2 antibody. DNA obtained was subjected 
to quantitative PCR using MMP13 promoter primers. Normal rabbit IgG and primers 
amplifying promoter region of MARK3 gene were used as negative control. Experiments 
were performed in two independent biological samples. Representative data is shown.   
 
 
 
54 
 
Since Akt is the major downstream effecter kinase of the PI3Kinase/Akt pathway 
the most common way by which this pathway affects the activity of various cellular 
proteins is by phosphorylation of target protein by Akt. We searched for potential Akt 
phosphorylated residues of Runx2 using motif scanner prediction tool 
(http://scansite.mit.edu). This software predicts optimal phosphorylation sites for 
particular protein kinases using the matrix of selectivity values for amino acids at each 
position relative to the phosphorylation site as determined from the oriented peptide 
library technique. In this technique, peptides that get phosphorylated by the kinase are 
isolated and sequenced as an ensemble by Edman degradation. When sequenced in 
this manner, each Edman cycle reveals the relative amount of each amino acid residue 
occurring at a particular position. This information is then scaled and normalized to 
produce a scoring matrix which quantitatively indicates the preference for each amino 
acid type at each position within the peptide motif. Scansite software scans any given 
protein sequence for matches to desired motifs in this peptide database. The program 
then indicates the percentile ranking of the candidate motif in respect to all potential 
motifs in proteins of a protein database. 
Scansite software identified nine amino acids in Runx2 as potential Akt 
phosphorylated residues. One residue in the amino terminus, five in the runt homology 
domain (RHD) and three amino acids in the carboxy terminus of Runx2 (Figure 18).  
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Figure 18: Predicted Akt phosphorylated residues in Runx2 protein 
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Figure 19: Predicted Akt phosphorylated residues are conserved through 
evolution 
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Though the surrounding amino acid sequence varied, these predicted Akt 
phosphorylated amino acids of Runx2 were conserved through evolution and were 
present in human, mouse, rat and zebra fish (Figure 19).  
 To test whether Akt could phosphorylate Runx2 protein, we purified bacterially 
expressed recombinant Runx2 to perform in vitro kinase assay. For this we transformed 
BL21 bacterial cells with Runx2- pGEX plasmid. This plasmid expresses Runx2 as an 
N-terminal GST fusion protein under the control of tac promoter. Runx2 expression was 
induced for one hour with IPTG followed by purification using glutathione beads.  
Purified GST-Runx2 was resolved by SDS PAGE gel followed by western blotting using 
Runx2 antibody to test the quality of the purified protein. As seen in Figure 20 very little 
full length protein was obtained by this method and the majority of protein appeared to 
be degraded.   
Analysis of the coding sequence (CDS) of Runx2 revealed an abundance of 
‘rare’ codons (Figure 21). Codons that appear in lower frequency in genes in E.coli than 
in the genes of eukaryotes are termed rare codons. The amount of specific tRNAs is 
also reflected by the frequency of the codon, meaning that a tRNA which recognizes a 
rarely used codon is present in low amounts. Therefore, genes that contain codons 
which are rare in E. coli may be inefficiently expressed by this organism. Rare codons 
cause premature termination of the synthesized protein or misincorporation of amino 
acids.  Clusters of rare codons stand a higher chance to create translation errors and 
reduce protein expression level. This problem can be solved either by exchanging 
codons in the target gene for codons which are more frequently used in E. coli or, 
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alternatively, by co-production of the rare tRNAs. To improve the quality of our protein 
preparation we used BL21 RP codon plus cells (Stratagene) for Runx2 expression. 
These competent cells contain extra copies of tRNA genes that are rare in E. coli but 
used more frequently in eukaryotes. As seen in Figure 22 GST-Runx2 protein purified 
by this method was of good quality and majority of the purified product was full length 
protein. 
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Figure 20: Purification of GST tagged Runx2 protein from BL21 cells.  
GST-tagged Runx2 protein expressed in BL21 cells was purified using glutathione 
beads. Purified protein was resolved by 10% SDS PAGE gel followed by western 
blotting using GST antibody to check the quality of the purified product.  
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Figure 21: Frequency of six least used E.coli codons in Runx2 coding sequence 
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Figure 22: Purification of GST tagged Runx2 protein from BL21 and BL21 RP cells 
 GST-tagged Runx2 protein expressed in BL21 or BL21 RP cells was purified using 
glutathione beads. Purified protein was resolved by 10% SDS PAGE gel followed by 
western blotting using GST antibody to check the quality of the purified product.  
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Runx2 is a direct substrate of Akt kinase. 
For in vitro kinase assay purified GST or GST- Runx2 protein were incubated with 
commercially available active Akt kinase in the presence of 32P γ-ATP in kinase buffer. 
The samples were resolved by SDS PAGE gel and autoradiographed to detect 
incorporation of radioactive phosphate. Akt kinase robustly phosphorylates GST-Runx2 
protein but fails to phosphorylate GST protein (Figure 23B).   
To delineate the domains of Runx2 which are phosphorylated by Akt, we tested 
the ability of Akt kinase to phosphorylate three deletion mutants of Runx2; (2-107) 
amino terminus, (107-241) runt homology domain (RHD) and (240-528) carboxy 
terminus by in vitro kinase assay. Akt phosphorylates all three domains of Runx2 
confirming motif scan prediction that Akt phosphorylates Runx2 at multiple residues 
(Figure 24). 
Next we mutated the nine serine and threonine residues in WT Runx2 which 
were predicted as potential Akt phosphorylated sites to alanine to generate GST tagged 
9A Runx2 protein and performed in vitro Akt kinase assay. Akt robustly phosphorylates 
GST-WT Runx2 but only weakly phosphorylates GST-9A Runx2 (Figure 25). These 
results indicate that Runx2 in a direct substrate of Akt kinase and that some or all of 
these nine residues are phosphorylated by Akt.   
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Figure 23: Runx2 is a direct substrate of Akt kinase 
A) Schematic illustration of domain organization of Runx2 with predicted Akt 
phosphorylated residues; N-ter, Amino terminus; RHD, runt homology domain (DNA 
binding domain); C-ter, Carboxy terminus. B) Bacterially expressed, purified GST or 
GST tagged full length Runx2 were subjected to Akt kinase assay. Proteins were 
resolved using 10% SDS PAGE and autoradiographed (left panel) or stained using 
coomassie blue (right panel). The asterisk (*) indicates a non specific band (NS). 
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Figure 24: Akt kinase phosphorylates all three domains of Runx2 
Bacterially expressed, purified domains (N-ter, RHD and C-ter) of Runx2 were 
subjected to Akt kinase assay. Proteins were resolved using 10% SDS PAGE and 
autoradiographed (top panel) or stained using coomassie blue (bottom panel). The 
asterisk (*) indicates autophosphorylation of Akt. 
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Figure 25: 9A Runx2 is minimally phosphorylated by Akt kinase  
 All predicted Akt phosphorylated residues were mutated to alanine to generate GST-
9ARunx2. GST-WT and GST-9A Runx2 were subjected to Akt kinase assay. Proteins 
were resolved using 10% SDS PAGE and autoradiographed (top panel) or stained 
using coomassie blue (bottom panel). 
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We further defined the exact Akt phosphorylation sites of Runx2 using in vitro 
kinase assays with a panel of synthetic peptides spanning putative phosphorylation 
sites (Figure 26).  Akt strongly phosphorylates four Runx2 peptides (respectively 
spanning amino acids S28, S125, S203/T205/T207 and S279), as well as weakly 
phosphorylates two other peptides (i.e., T227 and S474) (Figure 27). We were unable to 
synthesize peptide S347 due to techinical difficulties. Taken together these findings 
demonstrate that in vitro Akt phosphorylates Runx2 at several sites. 
To validate our in vitro data in mammalian cells we cloned WT and 9A Runx2 in 
mammalian expression plasmid; pCMV2. This construct expresses Runx2 as an N-
terminal FLAG fusion protein in cells. We obtained two constructs of Akt; constitutively 
active (CA) Akt and dominant negative (DN) Akt cloned in pcDNA3 plasmid. CA Akt has 
an amino terminal src myristoylation sequence which targets Akt to the plasma 
membrane independent of PtdIns-3,4,5-P3 where it gets phosphorylated by PDK1.  
Threonine 308 and serine 473 which are phosphorylated to activate Akt are mutated to 
alanine in DN Akt construct [111]. To assess in vivo phosphorylation of Runx2 in 
mammalian cells, FLAG tagged WT and 9A Runx2 were co-expressed with either 
constitutively active (CA) or dominant negative (DN) Akt constructs in 293T cells. Runx2 
was then immunoprecipitated and its phosphorylation levels in various samples were 
analyzed using a general phospho-serine/threonine antibody (pS/T). Runx2 was 
strongly phosphorylated when co-expressed with CA Akt, whereas significantly reduced 
phosphorylation was observed in the presence of DN Akt (Figure 28). As expected, the 
9A Runx2 mutant showed minimal Akt dependent phosphorylation. In addition treatment 
of western blot membrane with lambda phosphatase which removes phosphate 
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moieties form proteins prevented detection of pS/T antibody reactivity, thereby verifying 
the specificity of this antibody for phospho-proteins (Figure 29). Take together, these 
data show that Runx2 is a direct substrate of Akt kinase in mammalian cells. 
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                    Figure 26:  Peptides used for in vitro kinase assay 
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Figure 27: Peptide Kinase assay 
Peptides were subjected to in vitro Akt kinase assay. Samples were resolved on 20% 
Tris-tricine gel and autoradiographed. With the exception of T227 and S474 Akt strongly 
phosphorylated other Runx2 peptides. We were unable to synthesize peptide S347 due 
to technical difficulties.  
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Figure 28: Akt phosphorylates Runx2 in mammalian cells 
FLAG tagged WT and 9A Runx2 were co-expressed with constitutively active (CA) or 
dominant negative (DN) Akt in 293T cells. Runx2 was immunoprecipitated with FLAG 
beads and samples were resolved on 10%SDS PAGE gels. Blot was probed with a 
general phospho serine/threonine antibody (pS/T) to detect the phosphorylation level of 
Runx2 (top panel).The Arrow (       ) indicates specific band. The blot was reprobed with 
FLAG antibody to detect total Runx2 (bottom panel). 
 
 
 
71 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: pS/T antibody recognizes only phosphorylated proteins 
 FLAG tagged WT and 9A Runx2 were co-expressed with constitutively active (CA) or 
dominant negative (DN) Akt in 293T cells. Runx2 was immunoprecipitated with FLAG 
beads and samples were resolved by 10%SDS PAGE gel. Western blot membrane was 
treated for one hour with lambda phosphatase to remove phosphate moieties form 
proteins. Blot was probed with a general phospho serine/threonine antibody (pS/T) to 
detect the phosphorylation level of Runx2 (top blot). The blot was reprobed with FLAG 
antibody to detect total Runx2 (bottom blot). 
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Akt increases DNA binding of Runx2 by direct phosphorylation of its runt 
homology domain (RHD) independent of CBFβ 
We next asked whether phosphorylation by Akt can increase the DNA binding potential 
of purified Runx2 protein. We in vitro phosphorylated GST- tagged full length Runx2 by 
Akt in the presence of non radioactive ATP and used equal amounts of non 
phosphorylated and phosphorylated proteins for EMSA. Bacterially expressed purified 
Runx2 forms complex with the Runx consensus DNA oligonucleotide in the absence of 
Akt mediated phosphorylation. However, phosphorylation by Akt dramatically increases 
the affinity of Runx2 for its cognate site (Figure 30). These data show that 
phosphorylation by Akt kinase enhances the DNA binding potential of Runx2. 
Though Runx2 binds DNA through its RHD, the amino and carboxy terminus of 
Runx2 also regulate its DNA binding. Both these domains contain autoinhibitory regions 
that inhibit the DNA binding potential of Runx2 [112]. We wanted to analyze whether 
phosphorylation of RHD by Akt is sufficient to enhance its DNA binding potential or 
whether phosphorylation of amino or carboxy terminus of Runx2 relieves the inhibitory 
effect of these domains on the DNA binding of Runx2.  We in vitro phosphorylated GST- 
tagged RHD of Runx2 by Akt in the presence of non radioactive ATP and used equal 
amounts of non phosphorylated and phosphorylated RHD for EMSA. Similar to full 
length Runx2, phosphorylation by Akt dramatically increases the affinity of RHD for its 
cognate site (Figure 31). These data show that phosphorylation by Akt kinase enhances 
the DNA binding potential of Runx2 by direct phosphorylation of its runt  homology 
domain. 
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 In cells Runx2 interacts with CBFβ and this interaction increases the affinity of 
Runx2 to DNA and also stabilizes the protein. We tested whether in addition to directly 
increasing Runx2-DNA interaction, phosphorylation by Akt also affects Runx2/CBFβ 
interaction. We transiently co-expressed FLAG tagged WT Runx2 with either CA Akt or 
DN Akt constructs and analyzed Runx2/ CBFβ interaction by co-immunoprecipitation 
analysis. As seen in Figure 32 Akt signaling has no effect on Runx2/ CBFβ interaction. 
Thus, Akt phosphorylation directly impacts on the intrinsic DNA binding activity of 
Runx2.  
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 Figure 30:  Akt phosphorylation increases DNA binding of Runx2 
Bacterially expressed, purified Runx2 protein was subjected to Akt kinase assay. Equal 
amounts of non phosphorylated and phosphorylated proteins (p-Runx2) were used for 
EMSA to detect binding to Runx consensus oligonucleotide. Specificity of the Runx2 
complex was established using binding assays with unlabeled WT or mutant (MT) 
competitor oligonucleotides (left panel). Proteins were resolved by 10% SDS PAGE and 
probed with GST antibody and general phospho serine/threonine antibody (pS/T) (right 
panel). 
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Figure 31: Akt phosphorylation increases Runx2 DNA binding by direct 
phosphorylation of its DNA binding domain (RHD) 
Bacterially expressed, purified RHD of Runx2 was subjected to Akt kinase assay. Equal 
amounts of non phosphorylated and phosphorylated proteins were used for EMSA to 
detect binding to Runx consensus oligonucleotide. Specificity of the Runx2 complex 
was established using binding assays with unlabeled WT or mutant (MT) competitor 
oligonucleotides (left panel). Proteins were resolved by 10% SDS PAGE and probed 
with GST antibody (right panel). 
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 Figure 32: Akt signaling does not affect Runx2/CBFβ interaction 
FLAG tagged WT Runx2 was co-expressed with constitutively active (CA) or dominant 
negative (DN) Akt in 293T cells. Runx2 was immunoprecipitated with FLAG beads and 
samples resolved on 10% SDS PAGE gel to visualize Runx2 (top panel) and on 12% 
SDS PAGE gel to visualize CBFβ (bottom panel).  
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Akt phosphorylation deficient mutants of Runx2 show DNA binding and 
transcriptional potential 
 Since phosphorylation of the RHD was sufficient to enhance the DNA binding potential 
of Runx2, for our functional studies we made two mutants of Runx2 in which only the 
serine/ threonine residues in the RHD which were  predicted Akt phosphorylated 
residues were mutated to alanine. As seen in Figure 33A there is a cluster of three 
residues in the RHD that are predicted Akt phosphorylated residues. Out of these three 
T205 has the highest score for potential phosphorylation by Akt (Figure 33B). We made 
one Runx2 pCMV2 construct in which all three residues were mutated to alanine (S203/ 
T205 and S207, 3A Runx2) and another in which only S203 and T205 were mutated to 
alanine (2A Runx2). We first tested the phosphorylation levels and DNA binding 
potential of these two Runx2 mutants. We transiently co-expressed FLAG tagged WT, 
2A Runx2 and 3A Runx2 with either constitutively active (CA) or dominant negative 
(DN) Akt constructs in 293T cells  and  analyzed Runx2 phosphorylation levels in 
various samples using pS/T antibody. There is a progressive decrease in 
phosphorylation of Runx2 by Akt as predicted Akt phosphorylation residues are mutated 
to alanine (Figure 34A).  We analyzed the DNA binding potential of these two Runx2 
mutants by EMSA. As seen in Figure 34B both 2A and 3A Runx2 showed reduced 
binding to Runx consensus sequence as compared to WT Runx2. Taken together, our 
data show that mutation of specific Akt phosphorylation sites within the runt homology 
domain decreases the DNA binding potential of Runx2.   
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 We next analyzed the consequences of abrogating Akt mediated signaling 
through Runx2 on the expression of Runx2 responsive genes in breast cancer cells. 
Expression of the 2A or 3A mutant reduces the mRNA levels of two key metastasis 
related Runx2 responsive genes relative to WT (Figure 35). Both mutants retain proper 
sub-cellular localization in SUM159 breast cancer cells as determined by 
immunofluoresence microscopy (Figure 36). Thus, abrogation of critical Akt 
phosphorylation sites directly impinges on the expression of metastasis related Runx2 
responsive genes. 
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Figure 33: A) Schematic of cluster of predicted Akt phosphorylated residues in 
the DNA binding of Runx2 
 B) Comparison for Akt kinase site search by motif scan software 
Percentile ranking of predicted Akt phosphorylated residues in Runx2 protein. Low 
percentile ranking represents high probability of phosphorylation 
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Figure 34: Akt phosphorylation deficient mutants of Runx2 show reduced 
phosphorylation and DNA binding 
A) In vivo phosphorylation of WT and Runx2 mutants was examined by 
immunoprecipitation assays using FLAG-tagged WT, 2A and 3A Runx2 in 293 T cells 
that co-express constitutively active (CA) or dominant negative (DN) Akt. Runx2 
phosphorylation was monitored with the pS/T antibody as described previously (top 
panel). The arrowhead (      ) indicates specific band. The blots were reprobed with 
FLAG antibody to detect total Runx2 (bottom panel) 
B) DNA binding activity of in vitro transcribed and translated (IVTT) FLAG- tagged WT, 
2A and 3A Runx2 was measured by Electrophoretic Mobility Shift Assays (EMSA) using 
Runx consensus oligonucleotide. Specificity of the Runx2 complex was established 
using binding assays with unlabeled WT or mutant (MT) competitor oligonucleotides 
(top panel). Proteins were resolved by 10% SDS PAGE gel and probed with FLAG 
antibody (bottom panel).  
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Figure 35: Akt phosphorylation deficient mutants of Runx2 show reduced 
transcriptional potential in SUM159 breast cancer cells 
FLAG tagged WT, 2A and 3A Runx2 were over expressed in SUM159 using lentivirus 
and protein and RNA samples were collected. Total protein was used to detect Runx2 
by western blot analysis using FLAG monoclonal antibody (left panel). RNA was utilized 
to examine levels of Runx2 target genes (right panel). Data were normalized to mCox 
(mitochondrial cytochrome oxidase). Experiments were performed in two independent 
biological samples. Representative data is shown.   
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Figure36: Runx2 mutants show proper nuclear localization in breast cancer cells 
 SUM159 cell transfected with WT or Runx2 mutants were processed for insitu 
immunoflourescence. The cells were incubated with monoclonal antibody against FLAG 
tag followed by incubation with Alexa 488 conjugated secondary antibody to detect 
Runx2. DNA was visualized by DAPI (4', 6-diamidino-2-phenylindole) staining. Images 
were taken using Zeiss Axioplan digital microscope and Metamorph software was used 
for bio imaging. Bar represents 10µm. 
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Runx2 is an important downstream mediator of the PI3Kinase/Akt pathway for 
invasion of breast cancer cells 
 Our studies in highly metastatic SUM159 breast cancer cells demonstrate that 
the invasive potential of these cells is dependent both on aberrant Runx2 expression 
and activated PI3kinase/Akt signaling. To study the pathological role of Runx2 in 
invasion of breast cancer cells, we performed complementation experiments using WT 
and Akt site mutants of Runx2 in non-invasive MCF7 adenocarcinoma cells. These cells 
have barely detectable levels of endogenous Runx2 and an intact PI3kinase/Akt 
signaling axis. Forced expression of WT Runx2 increases invasion of MCF7 cells in 
Marigel transwell assay (Figure 37). Mutation of the main Akt phosphorylation sites in 
Runx2 (i.e., S203, T205, T207; mutants 2A and 3A) reduces the Runx2 dependent 
invasive potential of MCF7 (Figure 37). The extent to which invasion is decreased is 
proportional to the number of alanine substitutions (Figure 37), the phosphorylation 
status of the mutants (Figure 34A) and DNA binding activity (Figure 34B). Similar to 
results obtained with SUM159 cells, MCF7 cells expressing 2A or 3A mutant Runx2 
protein have lower mRNA levels of MMP9 and MMP13 than cells expressing WT Runx2 
(Figure 38). These results indicate that activation of the PI3kinase/Akt pathway and 
aberrant elevated expression of Runx2 both contribute to increased invasive potential of 
breast epithelial cells (Figure 39).  
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Figure 37: Runx2 is an important downstream mediator of PI3Kinase/Akt pathway 
for invasion of breast cancer cells (in vitro Matrigel invasion assay) 
MCF7 cells expressing WT or Runx2 mutants were plated on Matrigel inserts for 
invasion assay. Cells were allowed to invade for 72 hours at 37°C towards NIH3T3 
conditioned medium. We counted two random fields in two wells each for three 
independent experiments. The data are presented as the number of invaded cells per 
field (p values based on one-tailed Student’s t test are indicated). Representative 
images of cell expressing EV, WT and 3A Runx2 are shown. 
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Figure 38: Akt phosphorylation deficient mutants of Runx2 show reduced 
transcriptional potential in MCF7 breast cancer cells 
FLAG tagged WT, 2A and 3A Runx2 were over expressed in MCF7 cells using lentivirus 
and protein and RNA samples were collected. Runx2 was detected by western blot 
analysis using FLAG antibody (left panel). Endogenous mRNA levels of metastasis-
related Runx2 responsive genes were measured by RT-QPCR analysis of total cellular 
RNA. Data were normalized to mCox mRNA levels (right panel). Experiments were 
performed in two independent biological samples. Representative data is shown. 
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Figure 39: Model. PI3Kinase/Akt pathway modulates the DNA binding potential of 
Runx2 to regulate the expression of key genes involved in invasion of breast 
cancer cells 
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Discussion 
This study provides compelling evidence that Runx2 is a novel substrate of Akt in 
breast cancer cells and it acts as an important downstream mediator of PI3Kinase/Akt 
signaling to regulate breast cancer invasion. This finding is particularly important 
because the PI3kinase/Akt pathway is one of the major signaling pathways through 
which growth factors and other extracellular stimuli influence cellular growth, 
metabolism and invasion. In breast cancer cells, several mutations have been identified 
that hyper activate PI3Kinase/Akt signaling, which is essential to oncogenic 
transformation. Constitutive activation makes these cells independent of external 
metabolic cues and identifying downstream targets of this pathway is critical to 
understanding and controlling oncogenic growth, invasion and eventual treatment.   
  Runx2 protein has been shown to be expressed both in normal breast epithelium 
and breast cancer cells. Runx2 levels are very low in normal breast epithelial cells but 
its expression increases dramatically in breast cancer cells, with many metastatic breast 
cancer cell lines showing high expression of Runx2 protein. Although the mechanism by 
which breast cancer cells up regulate protein expression of Runx2 is yet to be identified 
several studies have shown that Runx2 enhances the metastatic potential of breast 
cancer cells by up regulating the expression of several factors that contribute to 
facilitating the process of metastasis, i.e., VEGF, several matrix metalloproteinases 
(MMP2, MMP9, MMP13) and bone sialoprotein (BSP). Interestingly, in three 
dimensional Matrigel cultures knocking down Runx2 results in complete phenotypic 
reversion of disorganized cancer cells (MDA-MB-231) to normal looking acinar 
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structures, reminiscent of normal breast epithelium [107].  In two dimensional cultures, 
knockdown of Runx2 reduces the invasive capabilities of these cells by down regulation 
of several metastasis related Runx2 targets [91, 92].  
  
We find that treatment of breast and prostate cancer cells with the PI3Kinase/Akt 
pathway inhibitor LY294002 severely inhibits Runx2 DNA binding thus preventing 
genomic interactions of Runx2 with its target promoters and subsequently causing down 
regulation of Runx2 target genes that are involved in tumor invasion (i.e., MMP13). We 
decided to investigate the regulatory interaction between Runx2 and Akt pathway which 
is conserved in multiple cell types. A sequence scan using the classical Akt consensus 
sequence (RXRXXS/T) first identified in GSK3β did not reveal a putative 
phosphorylation site. However Akt is now known to phosphorylate a multitude of 
substrates devoid of this consensus with high affinity. The motif scan program was 
developed using a database of peptide substrates to statistically predict the likelihood of 
any given sequence to be a kinase substrate. Motif scan predicted several putative Akt 
phosphorylation sites in Runx2. We showed that Akt phosphorylates Runx2 both in vitro 
and in vivo in all three domains of Runx2. We further investigated the DNA binding 
domain phosphorylations in Runx2 protein. Our study for the first time identified 
phosphorylation of a cluster of residues in the runt domain that increases the DNA 
binding potential of Runx2. Since these phosphorylations do not affect CBFβ interaction, 
they likely increase binding by inducing a conformational change in the DNA binding 
interface of Runx2.  
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Experiments in poorly invasive MCF-7 cancer cell line underscore the functional 
importance of this phosphorylation of Runx2 by PI3 Kinase/Akt pathway in regulating 
the invasive potential of breast cancer cells. This cell line has an intact PI3kinase/Akt 
signaling axis [113] but it shows very poor invasive/metastatic phenotypes. Expressing 
WT Runx2 which can respond to Akt signaling in these cells increases their invasive 
potential significantly but Runx2 mutants that do not respond to Akt signaling do not 
significantly affect the invasive properties of these cells. Thus cooperation of activated 
PI3kinase/Akt signaling and aberrant over expression of Runx2 together yields to these 
cells the full complement of characteristics to become malignant cells. 
 Our study shows that activated Akt signaling increases the transcriptional 
potential of Runx2 and consequently increases the metastatic properties of breast 
cancer cells. Clinical studies have independently shown both activated Akt signaling 
and Runx2 expression to positively correlate with breast cancer metastasis. The 
identification of Runx2 as a key downstream target of the PI3Kinase/Akt pathway 
provides a significant advance in understanding the interplay of these two crucial 
components in breast cancer cell invasion and metastasis. It would be interesting to 
determine the correlation between aberrant Runx2 expression, activated Akt and clinical 
behavior/prognosis in breast cancer.  
 Runx2 protein is shown to dynamically shuttle between the nucleus and 
cytoplasm and regulation of sub cellular localization of Runx2 is one of the mechanisms 
to modulate its transcriptional activity [114]. One interesting observation made during 
this study was that the majority of Akt phosphorylated motifs in Runx2 overlap with 
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predicted 14-3-3 binding motifs (scansite.mit.edu). Proteins belonging to the 14-3-3 
family bind primarily to phosphoserine residues present on target proteins and alter their 
subcellular localization [115]. Binding to 14-3-3 can sequester target proteins in 
cytoplasm by promoting nuclear export or blocking nuclear import.  Conversely 14-3-3 
proteins can also increase nuclear retention of target proteins [116]. Our preliminary 
data shows that treatment of SUM159 breast cancer cells with PI3Kinase/Akt inhibitor; 
LY294002 for prolonged time  periods (>16 hours) reduces the amount of Runx2 protein 
detected in nuclear extracts. Although further experiments need to be done to establish 
whether this reduction is due altered subnuclear localization of Runx2, reduction in total 
protein levels or both, it is possible that Akt mediated phosphorylation of Runx2 
generates docking sites for 14-3-3 proteins and this interaction retains Runx2 protein in 
the nucleus.  
 Runx2 is primarily expressed in osteoblasts where it acts a master regulator of 
bone formation. Multiple studies have shown that both IGF1/Akt axis and Runx2 are 
required for normal bone development. Runx2-/- mice show complete absence of bone 
formation [9]. Akt1-/- mice also show severe osteopenia due to defects in osteoblast 
differentiation [117]. Multiple studies have shown that cooperation between Akt 
signaling and Runx2 is required for osteoblast growth, survival and differentiation.  For 
example, Fujita and colleagues have shown that PI3K/Akt signaling greatly enhances 
DNA binding and transcriptional activity of Runx2 to mediate differentiation and 
migration of chondrocytes and osteoblasts [118]. However, their study did not 
investigate the mechanism of this effect. Our study in breast cancer cells corroborates 
the results obtained in osteoblast and chondrocytes and also provides a possible a 
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mechanism by which  Akt signaling can regulate the DNA binding potential of Runx2 in 
both bone and cartilage cells. It will be interesting to study in vivo the consequence of 
abrogating PI3kinase/Akt signaling through Runx2 on bone formation by generating 
Knockin mice with Akt phosphorylation deficient Runx2 mutants. Based on previous 
studies and our data, these mice are predicted to be phenotypically similar to Akt null 
mice and show significant osteopenia phenotype. 
  The sequence of runt domain is remarkably well conserved amongst all three 
Runx proteins. It is likely that Akt phosphorylation of Runx1 and Runx3 proteins also 
increases their DNA binding potential. In fact our preliminary data suggests that Akt 
indeed phosphorylates Runx1 in vitro.  Another interesting possibility is the regulation of 
DNA binding property of leukemogenic protein AML-ETO by Akt mediated 
phosphorylation.  AML-ETO is a fusion protein consisting of the NH2-terminal portion of 
the AML1 protein including the runt homology domain (RHD) fused in frame to the 
nearly full-length ETO protein (a known repressor protein) as a result of (8;21) 
chromosomal translocation. The RHD of Runx1 thus directs the fusion protein, with ETO 
associated repressor proteins, to the promoters of Runx1 regulated genes leading to 
dysregulation of genes central to myeloid cell functions [52]. Though expression of 
AML-ETO fusion protein is critical for leukemogenesis, cooperating mutations that 
activate growth factor signaling including FLT3, Ras or c-Kit mutations are required for 
the development of acute myeloid leukemia (AML) [119, 120].  These growth factor 
signaling mutations activate PI3 kinase/Akt signaling which regulates the growth, 
survival and apoptosis of these cells. Our data hints at direct regulation of DNA binding 
potential of AML-ETO by these cooperating mutations, which might be required for the 
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development of AML. The pathogenesis of this subset of leukemia has been shown in 
models to be inherently dependent on the dysregulation mediated by the aml-eto fusion 
protein on bona-fide/novel Runx1 targets. Our data suggests an exciting therapeutic 
avenue for the treatment of t 8:21 AML with Akt inhibitors. Akt inhibitors would be 
predicted to disrupt/reduce the fusion protein-DNA binding affinity and thereby  reduce 
the activity of this leukemogenic protein. 
  Akt kinase assay of Runx2 peptide also identified three additional peptides 
outside the runt domain that were phosphorylated by Akt. Serine 28, is a well known 
phosphorylation site on Runx2 protein indentified in several studies [100]. The effect of 
phosphorylation of this residue on Runx2 function is yet to be identified. The C terminus 
of Runx2 binds various transcription activators or co repressors to cause context 
dependent activation of repression of target genes. Phosphorylation of this domain of 
Runx2 might influence the interaction of Runx2 with these binding partners.  
Eukaryotic cells have three known isoforms of Akt (Akt1, Akt2 and Akt3) which 
are coded by three separate genes. Recently, it has been demonstrated that different 
isoforms of Akt have distinct and opposite effects on breast cancer invasion and 
metastasis. Akt2 enhances invasion [121] whereas Akt1 has been shown to inhibit 
tumor invasion [122]. Inhibiting both Akt isoforms has been shown to inhibit tumor cell 
migration and epithelial to mesenchymal transition [123] . Our study shows that 
inhibiting total Akt activity in SUM159 cells leads to decrease in cell invasion and that 
Runx2 is an important downstream mediator of this effect. It will be interesting to know if 
Runx2 is phosphorylated in an isoform specific manner by Akt in breast cancer cells. 
Given that Akt positively regulates Runx binding to metastasis related genes leading to 
  
transcriptional up regulation of these genes we postulate that Runx2 might be a target 
of AKT2 in breast cancer cells. 
In conclusion this work demonstrates clearly the biochemical mechanism by 
which Runx2, which itself is a well known player in breast cancer metastasis, is directly 
regulated by the PI3K/AKT pathway. While much is known about the signals that 
activate the PI3Kinase/Akt pathway, the identification of Runx2 as a key downstream 
substrate of PI3Kinase/Akt pathway provides a molecular mechanism to control tumor 
cell invasion and provides a potential novel therapeutic target in breast cancer. 
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Chapter 3 
Subnuclear targeting of the Runx3 tumor suppressor and its 
epigenetic association with mitotic chromosomes 
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Abstract 
Runx proteins are tissue-specific transcriptional scaffolds that organize and assemble 
regulatory complexes at strategic sites of target gene promoters and at intranuclear foci 
to govern activation or repression. During interphase, fidelity of intranuclear targeting 
supports the biological activity of Runx1 and Runx2 proteins. Both factors regulate 
genes involved in cell cycle control and cell growth (e.g., rRNA genes), as well as 
lineage commitment. Here, we have examined the subcellular regulatory properties of 
the third Runx member, Runx3, during interphase and mitosis. Using in situ cellular and 
biochemical approaches we delineated a subnuclear targeting signal that directs Runx3 
to discrete transcriptional foci that are nuclear matrix associated. Chromatin 
immunoprecipitation results show that Runx3 occupies rRNA promoters during 
interphase. We also find that Runx3 remains associated with chromosomes during 
mitosis and localizes with nucleolar organizing regions (NORs), reflecting an interaction 
with epigenetic potential. Taken together, our study establishes that common 
mechanisms control the subnuclear distribution and activities of Runx1, Runx2 and 
Runx3 proteins to support RNA polymerase I and II mediated gene expression during 
interphase and mitosis.  
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Introduction 
Fidelity of tissue specific gene expression necessitates integrating a broad 
spectrum of regulatory signals that governs proliferation, differentiation and further 
maintenance of gene expression patterns through cell cycle. In the cell it is essential to 
package 2.5 yards of DNA as chromatin within the limited confines of the nucleus. 
Furthermore, gene promoter elements must be rendered competent for protein/DNA 
and protein/protein interactions in a manner that permits binding and functional activities 
of primary transcription factors as well as with co-activators and co-repressors. In order 
to achieve these two disparate but equally important requirements, the cell maintains 
multiple levels of structural and functional organization. Several structural domains of 
the nucleus have been described such as nucleolus (rRNA transcription), histone locus 
bodies, cajal bodies, PML bodies and heterochromatin domains. The nuclear matrix 
provides a structural framework for organizing chromatin and nuclear 
proteins/transcription factors into distinct subnuclear domains that support replication, 
transcription and splicing within the interphase nucleus (Figure 40).  
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Figure 40: The nuclear architecture is functionally linked to the organization and 
sorting of regulatory information. 
 
 
                                                                      Stein et al. Integrative Biology (2011), 3: 297–303 
Reproduced by permission of The Royal Society of Chemistry 
  
DOI: 10.1039/c0ib00103a 
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During mitosis, the architectural organization of regulatory machinery in the 
nucleus undergoes major changes and the nuclear scaffold is disassembled. 
Competency for phenotype-restricted gene expression must be retained during mitosis 
for parental and progeny cells to remain structurally and functionally equivalent.  Data 
from our lab suggests that transcription factors that control tissue specificity remain 
complex with target gene loci of mitotic chromosomes to support post-mitotic gene 
expression. The retention of regulatory factors with gene loci is not confined to DNA 
polymerase II-mediated control. Several lines of biochemical and in situ evidence 
indicate transcription factors that regulate DNA polymerase I mediated expression of 
ribosomal RNA are retained during mitosis to epigenetically support competency for 
post-mitotic protein synthesis [124].  
Runx transcription factors provide a paradigm for the focal organization of 
transcriptional regulatory machinery in nuclear matrix associated punctate intranuclear 
domains during interphase (Figure 41) and epigenetic regulation of gene expression 
and lineage commitment during mitosis. During interphase, Runx1 and Runx2 proteins 
are shown to be associated with the nuclear matrix through a 31–35 amino acid nuclear 
matrix targeting signal (NMTS) in the carboxy terminus [23]. Here they act as 
scaffolding proteins that assemble regulatory complexes at specific intranuclear sites to 
mediate activation or repression of target genes. Fidelity of nuclear matrix association is 
important for the biological activity of these transcription factors. Defective subnuclear 
targeting of Runx1 and Runx2 leads to defects in hematopoiesis and bone 
differentiation, respectively [125, 126].  
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During mitosis Runx1 and Runx2 proteins remain associated with the nucleolar 
organizing regions (NORs) of acrocentric chromosomes, and this association requires 
the DNA binding domain. Discrete Runx foci at NORs colocalize with UBF1, a principal 
regulator of Pol I gene transcription that is required for rRNA synthesis (Figure 42) [127, 
128]. Consistent with the anti-proliferative role of Runx2 in osteoblasts, binding of 
Runx2 to the rDNA promoter downregulates rRNA transcription [128]. These previous 
studies from our group together indicate that Runx1 and Runx2 may regulate cell 
proliferation by coordinating cell cycle kinetics with control of cell growth. 
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Figure 41: Runx2 protein is directed to discrete nuclear matrix associated 
subnuclear domains. 
  Electron microscopy of the nuclear matrix (NM) (left panel). Immunofluorescence 
microscopy of endogenous Runx2 in ROS 17/2.8 cells showing foci associated with the 
NM obtained by in situ extraction of soluble chromatin (NM intermediate filament 
preparation). 
 
                                                                    Stein et al.  Integrative Biology (2011), 3: 297–303          
Reproduced by permission of The Royal Society of Chemistry 
DOI: 10.1039/c0ib00103a 
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 Figure 42: Runx2 protein remains associated with the nucleolar organizing 
regions (NORs) of acrocentric chromosomes during mitosis 
 Runx2 (green) colocalizes with UBF1 (red), a principal regulator of Pol I gene 
transcription that is required for rRNA synthesis. Colocalization; yellow                                                                         
 
 
                                                                                                         Figure contributed by Jason Dobson 
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Runx3 is the smallest protein of the Runx family in mammals. It is located on 
chromosome 1p in humans and on chromosome 4 in mice. Aberration in the short arm 
of chromosome 1 is observed in many human cancer specimens. Indeed between 45% 
and 60% of human gastric cancer cells do not significantly express Runx3 due to 
hemizygous deletion and hypermethylation of the Runx3 promoter region [41]. 
Furthermore, a significant percentage of Runx3 positive gastric tumor specimens and 
cell lines show mislocalization of the protein to the cytoplasm where it is inactive [40]. 
Runx3 is also shown to inhibit growth of primary gastric epithelium and gastric cancer 
cell lines in vitro in both transforming growth factor beta (TGFβ) dependent and 
independent manner [129]. Runx3 is therefore considered a tumor suppressor of gastric 
epithelial cells.  
As observed for Runx1 and Runx2, Runx3 is predominantly a nuclear protein that 
is punctately organized. However, mechanisms associated with Runx3 subnuclear 
localization remain to be investigated. In the present study, we identify and characterize 
the NMTS of Runx3 and show that subnuclear targeting of Runx3 contributes to its 
transcriptional activity. We also demonstrate that Runx3 is retained on mitotic 
chromosomes in large discrete foci, co-localizes with UBF1 and occupies rDNA 
promoters. Taken together, we have established that common mechanisms control 
subnuclear localization and activity of Runx proteins in interphase and mitosis. 
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Materials and Methods 
 
Cell Culture and Transient Transfections: 
All cells were grown in 37˚C incubators in DMEM media supplemented with 10% fetal 
bovine serum, and 2mM L-glutamine. HeLa cells were transfected using FuGENE-6 
(Roche) according to manufactures instructions. 
 
Biochemical Fractionation: 
24 hours after transfection, HeLa cells were processed for biochemical fractionation as 
described previously [23]. Briefly, for whole-cell lysate, cells were lysed in direct lysis 
buffer (2% SDS, 2 M urea, 10% glycerol, 10 mM Tris-HCl (pH 6.8), 0.002% 
bromophenol blue, 10 mM DTT and 1× Complete protease inhibitors (Roche)). Samples 
were boiled and stored at −70°C. For subcellular fractionation, cells were harvested in 
ice-cold PBS containing protease inhibitors. Cell pellets were resuspended in 300 μl 
CSK buffer (100 mM NaCl, 0.3 M sucrose, 10 mM Pipes, 3 mM MgCl2, 1 mM EGTA, 
0.5% Triton X-100, pH 6.8) and incubated for 10 minutes on ice. Extracted cells were 
centrifuged to collect nuclei. The supernatant containing cytosolic proteins was frozen in 
liquid nitrogen and stored at −70°C. Nuclei were extracted with 300 μl digestion buffer 
(50 mM NaCl, 0.3 M sucrose, 10 mM Pipes, 3 mM MgCl2, 1 mM EGTA, 0.5% Triton X-
100, pH 6.8) containing 400 U DNaseI (Roche) for 30 minutes at room temperature. 
DNaseI was inactivated by adding 2 M ammonium sulfate to a final concentration of 250 
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mM for 5 minutes at room temperature. Extracted nuclei were centrifuged to separate 
soluble nuclear proteins (chromatin fraction) and insoluble nuclear-matrix-intermediate 
filament fraction (NM-IF). The NM-IF fraction was then boiled in 300 μl of direct lysis 
buffer for 5 minutes. The same volume percentage of each fraction was analyzed by 
10% SDS-PAGE and western blotted using anti-Flag (Upstate) anti-Cdk2 (Santa Cruz) 
or anti-Lamin B (Santa Cruz) antibodies.   
 
Luciferase Reporter Assay 
HeLa cells were co-transfected with 100 ng expression constructs and 500ng Firefly 
luciferase reporter and 10 ng Renilla as a control for transfection efficiency.  24 hours 
after transfection cells were harvested in 250 µl of 1x Reporter Lysis Buffer (Promega) 
and the lysates were processed for luciferase assay.  Luciferase activity was assessed 
with a dual Luciferase Assay Kit according to manufacturer’s instructions (Promega) 
 
Western Blot 
Protein extracts were diluted in 4X sample loading buffer (250mM Tris pH 6.8, 8%SDS, 
40%glycerol and 100mM DTT), boiled for 5 min and centrifuged at 16,000 × g for 1 min.  
Appropriate amounts were loaded onto 10% SDS-polyacrylamide gels and transferred 
to a polyvinylidene difluoride (PVDF) Immobilon-P membrane (Millipore) for 90 minutes 
at 200mA in a wet transfer apparatus (Biorad). Membrane was incubated with 
appropriate dilution of specific primary antibodies followed by incubation with 
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corresponding HRP tagged secondary antibodies. Desired proteins were detected with 
Western Lightning Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences) 
Chromatin Immunoprecipitation 
IEC-6 rat gastric epithelial cells were cross linked in 1X PBS with 1% formaldehyde for 
~3 min and the reaction was quenched by the addition of glycine at a final concentration 
of 250 mM for 10 min. Cells were washed with PBS and incubated in lysis buffer A (50 
mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA pH 8, 10% Glycerol (Sigma G5 150), 
0.5% NP-40 (Igepal CA-630, Sigma), 0.25% Triton X-100, 25μM MG-132, 1X Complete 
protease inhibitor (CPI) cocktail (Roche)), to lyse the cells. Cells were centrifuged for 10 
minutes and the pellet was resuspended in lysis buffer B (10 mM Tris-HCl pH 8, 200 
mM NaCl, 1 mM EDTA pH 8, 1 mM EGTA, MG-132, 1X CPI). for 10 min, followed by 
centrifugation for 5 min at 40C. Pellet was resuspended in lysis buffer C (10 mM Tris-
HCl pH 8, 100 mM NaCl, 1 mM EDTA pH 8, 1 mM EGTA, 0.1% Sodium deoxycholate 
(Sigma), 0.5% N-lauroylsarcosine (Sigma), MG-132, 1X CPI) and incubated on ice in 
order to release the chromatin fraction. Chromatin was fragmented  with Fisher 
Scientific Sonic Dismembrator fitted with a 1.6mm tip (Fischer Scientific) at power 10%, 
7 Pulses (10seconds each) to generate DNA fragments of approximately 1 Kb.  After 
sonication cell debris was removed by centrifugation at 14,000g for 5 min. One percent 
of the supernatant was kept as input. Rest of the supernatant containing protein-DNA 
complexes was incubated overnight with 4 μg of  Runx3 antibody (Santa Cruz) and 4μg 
of normal rabbit IgG (Santa Cruz) followed by 3 hr incubation with protein A/G-
conjugated agarose beads (Santa Cruz).  Protein A/G bead complexes were washed 
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with the following buffers: low salt (20mM Tris-Cl, pH 8.1, 150mM NaCl, 1% Triton X-
100, 2mM EDTA, 1X Complete protease inhibitor cocktail), high salt (20mM Tris-Cl, pH 
8.1, 500mM NaCl, 1% Triton X-100, 2mM EDTA), LiCl buffer (10mM Tris-Cl, pH 8.1, 
250mM LiCl, 1% Sodium deoxycholate, 1% Nonidet P-40, 1mM EDTA), and twice in TE 
(10mM Tris-Cl, pH 8.1, 1mM EDTA) protein-DNA complexes were eluted in 1% 
SDS/100mM NaHCO3 (elution buffer) and cross-linking was reversed by incubation at 
65oC for overnight in elution buffer and 300mM sodium acetate (pH 5.2).  Later DNA 
was purified by phenol-chloroform extraction followed by ethanol precipitation and then 
resuspended in TE for quantitative PCR. ChIP enrichment was determined as a 
quantitative measure reflecting the percentage of input. Primers used are: -  
rrDNA3.1 (F) GCTCGTATTCCCGTCCAGT; (R) AGCACCACATCGATCCAAC.   
tublin3’UTR (F) TGAGGAGGAGGTGGCTTAG;  (R) ACAGGACAGCAAATGCACAG. 
In Situ Immunofluorescence microscopy 
 Hela cells grown on gelatin-coated cover slips were transfected with various Runx3 
constructs and processed for in situ immunofluorescence the next day. In brief, cells 
were rinsed twice with ice cold PBS and fixed using 3.7% formaldehyde in PBS for 10 
min on ice. After washing once with PBS, cells were permeabilized in 0.1% Triton X-100 
in PBS for 15 to 20 min and washed twice with PBSA (0.5% BSA in PBS). Fixed cells 
were incubated for 1 hr with primary antibody at 37oC ( Sigma FLAG M2).  Cells were 
extensively washed with PBSA and incubated with FITC conjugated secondary antibody 
at 37oC. Nuclear DNA or chromosomes were visualized by DAPI (4', 6-diamidino-2-
phenylindole) staining.  Images were recorded using an Epifluorescence Zeiss Axioplan 
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2 (Zeiss MicroImaging) microscope equipped with a charged coupled device. Images 
were captured and analyzed by MetaMorph Imaging Software (Molecular Devices). 
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Results 
Runx3 resides in distinct nuclear matrix associated foci in interphase cells. 
Runx proteins have important biological activities that control cell fate 
determination, as well as cell growth and differentiation. Runx1 and Runx2 are targeted 
to subnuclear foci associated with the nuclear matrix, which is a nuclear scaffold where 
regulatory machinery for gene expression is organized. We investigated whether Runx3 
is also targeted to the nuclear matrix compartment. Transiently expressed Runx3 
exhibits a focal nuclear pattern and these foci are retained upon removal of soluble 
proteins, chromatin and associated components as reflected by loss of DAPI signal 
(Figure 43). To confirm nuclear matrix association we performed biochemical 
subcellular fractionation of Hela cells transiently expressing Runx3 followed by western 
blotting with a Flag antibody (Figure 44). While Cdk2 is enriched in the cytoplasmic 
fraction, Runx3 is predominantly detected in the nuclear matrix fraction together with 
Lamin B, a marker for the nuclear lamina. Hence, similar to other Runx proteins, Runx3 
is an integral component of the nuclear matrix. 
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Figure 43: Runx3 resides in distinct nuclear matrix associated subnuclear 
domains. 
 Hela cell transfected with full length Runx3 construct were processed for NM-IF 
preparation and insitu immunoflourescence. The cells were incubated with monoclonal 
antibody against Flag tag followed by incubation with Alexa 488 conjugated secondary 
antibody to detect Runx3. Images were taken using Zeiss Axioplan digital microscope 
and Metamorph software was used for bio imaging.   
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Figure 44: Subcellular fractionation of Hela cells transiently expressing full length 
Runx3.  
Hela cells expressing full length Runx3 construct were subjected to biochemical 
fractionation 24 hrs after transfection. Fractions were run on a 10% SDS PAGE gel 
followed by western blotting. Monoclonal FLAG antibody was used to detect Runx3. 
LaminB and Cdk2 are controls to show proper fractionation.  
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A specific carboxy terminal targeting signal directs Runx3 to subnuclear sites in 
interphase. 
Both Runx1 and Runx2 contain similar nuclear matrix targeting signals that 
support the trafficking of these regulatory factors to functional sites within the nucleus. 
The C-terminus of Runx3 has a segment of about 40 amino acids (residue 280-327) 
that shares significant homology with these nuclear matrix targeting signals (Figure 45). 
To address whether this sequence directs Runx3 to the nuclear matrix, we utilized a 
panel of epitope tagged C-terminal deletion constructs of Runx3 that were transfected 
into HeLa cells (Figure 46A). Western blot analysis shows that all deletion proteins are 
expressed at comparable levels (Figure 46B).  Subcellular fractionation combined with 
western blotting of Hela cells transiently expressing Runx3 deletion mutants show that 
deletion of amino acid (aa) residues 283-325 causes a dramatic change in the 
partitioning between chromatin and nuclear matrix fractions (Figure 47). We 
subsequently assessed the nuclear matrix association of the proteins at single cell level 
by immunofluoresence microscopy. Consistent with the subcellular fractionation results, 
deletion mutants of Runx3 that retain aa 283-325 are associated with the nuclear 
matrix, whereas deletion of this peptide motif causes loss of association of the protein 
with the nuclear matrix (Figure 48). Taken together, these results indicate that the 
domain containing aa 283-325 represents the nuclear matrix targeting signal of Runx3. 
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Figure  45: Sequence comparison of Nuclear Matrix Targeting Signal (NMTS) of all 
three Runx proteins 
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Figure 46: Amino acid sequence 283-325 of Runx3 is similar to the Nuclear Matrix 
Targeting Signal (NMTS) of other Runx proteins.  
A) Schematic representation of full length Runx3 and its deletions. B) Deletions of 
Runx3 are expressed at comparable levels in Hela cells. Total protein extracts were 
prepared from Hela cells 24 hours after transfection with full length Runx3 or its 
deletions. Equal amounts of protein were loaded in each lane. Western blot using FLAG 
antibody reveals that all constructs are expressed at similar levels. Lamin B is used as 
loading control. 
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Figure 47: Subcellular fractionation of Hela cells transiently expressing full length 
Runx3 or its deletions.  
Hela cells expressing various deletion constructs of Runx3 were subjected to 
biochemical fractionation 24 hrs after transfection. Fractions were run on a 10% SDS 
PAGE gel followed by western blotting. Monoclonal FLAG antibody was used to detect 
proteins. LaminB and Cdk2 are controls to show proper fractionation.   
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Figure 48: Immunoflourescence microscopy of Hela cells transiently expressing 
full length Runx3 or its deletions.  
Hela cells transfected with various Runx3 deletion constructs were processed for NM-IF 
preparation and in situ immunoflourescence. Images were taken using Zeiss Axioplan 
digital microscope and Metamorph software was used for bio imaging.  
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Transcriptional activity of Runx3 is regulated by its association with nuclear 
matrix.  
We analyzed the ability of Runx3 and all six deletion mutants to activate a luciferase 
reporter under control of multimerized Runx binding element fused to a minimal 
promoter. Full length Runx2 and Runx3 robustly activate the reporter plasmid, but 
Runx3 mutants that lack the NMTS (i.e. 1-187, 1-234 and 1-283) fail to significantly 
activate the luciferase reporter above empty vector level. Mutants 1-373 and 1-410 
activate the reporter similar to WT protein. Mutant 1-325 failed to activate the reporter 
even though it has the NMTS indicating that residues located C-terminal of Runx3 
NMTS are required for Runx3 mediated transactivation (Figure 49).  
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Figure 49: Transcriptional activity of Runx3 is regulated by its association with 
nuclear matrix.  
HeLa cells grown on six- well plates were co-transfected with 100 ng of indicated 
expression constructs and 500ng Firefly luciferase reporter and 10 ng Renilla as a 
control for transfection efficiency.Runx2 serves as a positive control. Twenty four hours 
after transfection cells were harvested in 1x Reporter Lysis Buffer and the lysates were 
processed for luciferase assays. Firefly values were normalized with respective Renilla 
values and plotted. Transfections were done in triplicates. Error bars represent SD 
between the triplicates. 
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Runx3 associates with mitotic chromosomes and occupies the rRNA promoter.  
When cells prepare for mitosis, the chromosomes condense, subnuclear organization is 
altered and the nuclear envelope disassembles. Cell fate determining transcription 
factors such as Runx1 and Runx2 remain associated with mitotic chromosomes. 
Because Runx1 and Runx2 epigenetically regulate phenotypic genes and ribosomal 
RNA genes to maintain lineage commitment and growth of progeny cells, we analyzed 
the subcellular distribution of Runx3 during mitosis. In transiently transfected cells, 
Runx3 foci remain associated with chromosomes during mitosis. These foci co-localize 
with UBF1, a principal component of the RNA polymerase I (Pol I) controlled rRNA 
transcription machinery and a defining marker of the nucleolar organizing regions 
(NORs) in mitotic chromosomes. This association of Runx3 and UBF1 becomes 
prominent during prophase and persists through anaphase, but is no longer apparent 
when the nuclear architecture reassembles during telophase (Figure 50). Thus, the 
association of Runx3 with NORs suggests that Runx3 is an epigenetic regulator of gene 
expression similar to Runx1 and Runx2.  
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Figure 50: Runx3 co localizes with UBF1 on mitotic chromosomes. 
 Immunoflourescence microscopy for Runx3 (green) and UBF1 (red) with DAPI staining 
(blue) and overlay for co localization. Hela cells transfected with full length Runx3 were 
processed for insitu immunoflourescence microscopy. Cells were incubated with 
monoclonal antibody against Flag tag and polyclonal UBF1 antibody followed by 
incubation with anti mouse Alexa 488 conjugated and anti rabbit Alexa 568 conjugated 
secondary antibody to detect Runx3 and UBF1 respectively. Images of cells in various 
stages of mitosis were taken using Zeiss Axioplan digital microscope and Metamorph 
software was used for bio imaging.   
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Runx3 occupies ribosomal rRNA promoters in gastric epithelial cells. 
The in situ interaction of Runx3 with ribosomal DNA repeats to control rRNA 
transcription was biochemically validated by chromatin immunoprecipitation (ChIP) 
analysis. We used PCR primers that selectively amplify the ribosomal RNA promoter 
and IEC-6 gastric epithelial cells that endogenously express Runx3 as established by 
western blotting (Figure 51). ChIP results show that rRNA promoter fragments are 
selectively amplified in Runx3 immuonoprecipitates while the tubulin 3’ UTR (which 
serves as a negative control) is not (Figure 51). We conclude that endogenous Runx3 
occupies ribosomal rRNA promoters in gastric epithelial cells consistent with its in situ 
localization with NORs. 
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Figure 51: ChIPs with Runx3 and IgG antibodies show Runx3 binding to the rDNA 
promoter but not to the 3’ UTR of tubulin gene in IEC-6 gastric epithelial cells. 
 IEC-6 cells which express endogenous Runx3 (right panel) were processed for 
chromatin immunoprecipation using Runx3 antibody and normal rabbit IgG. The 
pulldown samples were amplified using rat rDNA promter primer (rrDNA_3.1) and tublin 
3’ UTR primer which serves as a negative control. Pulldown by normal Rabbit IgG 
serves as control for nonspecific pulldown of genomic DNA (left panel). 
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Discussion 
In this study, we have delineated a subnuclear targeting signal (aa 283–325) that 
directs the tumor suppressor protein Runx3 to discrete transcriptional foci that are 
nuclear matrix associated. We also establish that Runx3 remains associated with 
chromosomes during mitosis and localizes at NORs. Thus, our study provides a 
molecular basis for the tight association of Runx3 with components of nuclear 
architecture.  
Apart from subnuclear compartmentalization, Runx proteins exhibit dynamic 
shuttling between nuclear and cytoplasmic compartments. For example, we have shown 
that the presence of Runx2 in the nucleus is controlled by the balance between 
microtubule dependent import and CRM1 dependent (i.e., leptomycin-sensitive) nuclear 
export in human osteosarcoma cells [114]. In our study, we observed that both full 
length Runx3 and a deletion mutant spanning 1–187 are both present in the nucleus of 
HeLa cervical carcinoma cells as established by IF and biochemical fractionation 
followed by western blotting. Earlier studies have shown that the 1–187 deletion mutant 
of Runx3 localizes to the cytoplasm of SNU16 gastric cancer cells [40]. However, 
endogenous Runx3 protein is also present in the cytoplasm and enters the nucleus only 
on stimulation of these cells by TGFβ [129]. Thus, there appear to be cell type-specific 
differences in the nuclear localization of Runx3 between SNU16 cells and HeLa cells. It 
is possible that Runx3 expressed in HeLa cells may not be subjected to nuclear export 
or that the protein is not sequestered in the cytoplasm. 
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 The targeting of Runx3 to the nuclear matrix may have significant biological 
consequences as the transcriptional activity of the closely related Runx1 and Runx2 
proteins is regulated by association with the nuclear matrix. The nuclear matrix targeting 
signals of Runx1 and Runx2 overlap their transcriptional activation domains, and the 
NMTS supports the in situ integration of cell signaling and transcriptional responses at 
target genes. Compromised subnuclear targeting of these proteins has been linked to 
defects in cellular maturation in both myeloid and bone lineages, as well as to increased 
tumorogenic potential of cells [23, 51, 125]. We propose that disruption of Runx3 
subnuclear targeting may abrogate target gene activation and have important 
pathological implications for the development of gastric tumors.  
During mitosis, the nuclear envelope and matrix are disassembled, chromatin 
condenses to form distinct chromosomes, and a large number of transcription factors 
are displaced from their target promoters or are degraded during mitotic gene silencing. 
Our previous studies have shown that lineage specific transcription factors that include 
Runx2 remain associated with chromosomes during all phases of mitosis through 
sequence specific DNA binding. A large number of cell cycle control and lineage 
commitment genes are mitotically regulated by Runx2, thus providing a critical 
regulatory function in progeny cells for post mitotic gene expression in G1 [127]. On the 
mitotic chromosomes, Runx2 not only associates with Pol II dependent genes but also 
represses Pol I dependent transcription of ribosomal RNA genes [128]. We report here 
that Runx3 is retained on the chromosomes of mitotic cells where it associates with 
UBF1, a principal component of the rRNA transcription machinery and remains 
associated with the ribosomal gene promoter as shown by ChIP assays. Loss of growth 
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regulation and enhanced protein synthesis are hallmarks of transformation. 
Downregulation of Runx1 and Runx2 modulates rRNA synthesis and protein synthesis 
capacity [128, 130]. The association of Runx3 with mitotic chromosomes and 
specifically with the promoter of ribosomal RNA genes raises the possibility that loss of 
Runx3-mediated tumor suppression may deregulate epigenetic control and protein 
synthesis during gastric tumor development. 
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CHAPTER 4 
Summary 
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  Summary 
 
Runx family of transcription factors plays an important role in mammalian 
development by regulating the expression of key genes involved in cell proliferation, 
differentiation and growth. A common theme in the functioning of these proteins is that 
they regulate development at specific decision points where cell fate is balanced 
between proliferation, differentiation and cell death 
 Runx proteins bind multiple interaction partners (activators, repressors, 
chromatin modifying factors, and other transcription factors) and  have the ability to 
associate with the ribo-nucleoprotein scaffold of the nucleus, the nuclear matrix.   Here 
they act as foci for assembly of regulatory complexes that integrates multiple signals to 
allow activation or repression of  target genes. Indeed, study of these proteins has 
developed as a paradigm for functional regulation in the context of distinct spatial 
regions of the nucleus.  
Proper sub nuclear targeting is critical for both Runx1 and Runx2 function. 
Various studies have delineated a conserved, 31-38 amino acid sequence present in 
both these  proteins that directs them to the nuclear matrix. Runx mutants with disrupted 
NMTS are unable to associate with the nuclear matrix and consequently have severely 
impaired transcriptional  potential. Runx3 protein has a similar sequence in its carboxy 
terminus, and in this thesis we characterize the NMTS of Runx3 protein using a panel of 
deletion constructs. We further show that presence of the NMTS is a pre-requisite for 
the normal transcriptional activity of Runx3 protein.  
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We also extend the potential role of Runx3 in lineage commitment and 
maintenance. Most common transcription factors have been shown to dissociate from 
the DNA during mitosis. However, studies have shown that certain lineage specific 
transcription factors remain associated with chromatin and partition into daughter cells 
in order to maintain cell identity. It has been shown by our lab that Runx2 is associated 
with mitotic chromosomes and it regulates both Pol I and Pol II dependent gene 
transcription. In this thesis we show that similar to Runx2, Runx3 associates with mitotic 
chromosomes and colocalizes with UBF1, a principal component of Pol I mediated 
rRNA transcription machinery. Our work demonstrates that mitotic association and 
epigenetic regulation is a common theme of all three Runx proteins underlying their 
importance in lineage commitment and maintenance. Loss of Runx3 has been shown to 
be an important step in gastric cancer progression hence deregulation of this lineage 
maintenance function of Runx3 is likely to be an important contributor to tumorigenesis.  
The activity of Runx proteins is tightly regulated during development and 
adulthood. Cells modulate the activity of Runx proteins in response to various extra 
cellular cues through complex signaling networks. Aberrant expression of Runx proteins 
is widely associated with various cancers where they can act as both tumor suppressors 
and oncogenes in a context dependent manner. Therefore it is critical to understand the 
mechanisms that regulate the activity of these transcription factors. 
As the other major facet of this thesis, we identify and describe the mechanistic 
basis of the well observed cooperation between PI3kinase/Akt signaling and Runx2 
activity. Physiologically,  Runx2 and  PI3kinase/Akt signaling are required for 
osteogenesis and maintenance of bone mass. Pathologically, both Runx2 and 
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PI3Kinase/Akt signaling axis enhance the metastatic properties of breast and prostate 
cancers. Despite numerous studies documenting the cooperation between Runx2 and 
the PI3kinase/Akt pathway, the mechanism of this cooperation was still unknown.    
 In this work we discover that Runx2 is a direct substrate of the Akt kinase. We 
also identify three critical residues in the RHD of Runx2 that mediate increased DNA 
binding affinity upon phosphorylation by Akt. Mutation of these residues dramatically 
reduces the expression of Runx responsive genes that regulate the invasive properties 
of breast cancer cells. The identification of Runx2 as a key downstream substrate of 
PI3Kinase/Akt pathway identifies a molecular mechanism to control tumor cell invasion 
and provides a potential novel therapeutic target in breast cancer.  
The importance of the regulatory interaction between PI3Kinase/Akt signaling 
and Runx2 is further underscored by the fact that these three sites are conserved in all 
three Runx proteins. Indeed, preliminary data shows that both Runx1 and AML-ETO are  
phosphorylated by Akt, thus raising the possibility that regulation of DNA binding by the 
Akt kinase is a common theme amongst all Runx proteins.  
In conclusion, this thesis describes the regulation of two members of Runx 
protein family i.e., Runx2 and Runx3. We show that a common theme is seen in the 
regulation of  all Runx family members. Our findings provide new insights and pave way 
for further study into the regulation of this family of transcription factors.  
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Runx1 is a Direct Substrate of Akt 
 In chapter Two of this thesis we describe the phosphorylation of Runx2 protein by Akt.  
Runx family members have highly similar sequence and structure, so it is not surprising 
that the Akt phosphorylated residues of Runx2 are conserved in other Runx proteins 
(Figure 52).  We did preliminary experiments to verify that other Runx family members 
are also targets of Akt kinase. We subjected bacterially expressed, purified GST tagged 
Runx1 protein to in vitro kinase assay using GST- Runx2 protein as positive control for 
the experiment. As seen in Figure 53 Akt robustly phosphorylated both Runx2 and 
Runx1 protein. 
Runx1 protein is required for definitive hematopoiesis and is a frequent target of 
genetic aberrations that cause leukemia. Our Runx2 data suggests, that 
phosphorylation   of Runx1 by Akt can potentially affect DNA binding of Runx1. It will be 
interesting to see how PI3kinase/Akt signaling affects Runx1 function in normal 
hematopoiesis and malignant hemopathies. 
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Figure 52: Potential Akt phosphorylation sites  on other Runx family members 
Runx3 
Runx1 
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Figure 53: Runx1 is a substrate of Akt kinase. 
Bacterially expressed, purified GST- Runx1 or GST -Runx2 were subjected to Akt 
kinase assay. Samples were resolved on 10% SDS PAGE gel and autoradiographed 
(left panel). Coomassie stained gel is shown (right panel). 
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